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In view of the recent work on isolated cardiac muscle which has shown that
situations can occur in which the force and velocity of contraction are chanced
in different directions, we have questioned the usefulness of the search for a
single index of contractility related to the rate of rise of tension, a trend
which dominates studies of the heart in vivo. He have attempted to show, in
the heart in vivo, that situations do occur in which the duration of contraction
can determine the force of contraction or in. which force and velocity of contraction
are changed in different directions such that purely a change iu the velocity
dependant aspects of contraction would not describe the inotropic intervention.
Tog hearts have been prepared in situ so that heart rate (III), left ventricular
end diastolic pressure (LVEDP) and mean aortic pressure (HAP) can be controlled
separately during computation of left ventricular dP max and external stroke work' (SW).
dt
Progressive increases in HR consistently raised £fP max ever a wide range, and
dt
consistently lowered SW except at low rates. Progressive increases in LVEDP or
MAP consistently raised both cVP max and SW. Infusion of noradrenaline consistently
dt
raised both &P max and SW, except at very high HE when only c[E max was consistently
dt dt
raised.
We have investigated the haemodynamic effects of sotalol and bretylium which have
been reported to increase the force of contraction by prolonging the duration of
thQ contraction in isolated cardiac muscle. We were unable to show that these
drugs produced divergent effects on dP max and SW. although sotalol but not bretylium
dt
did prolong the duration of contraction.
We also investigated the cardiovascular effects of prostaglandins C and E and found
that both prostaglandins have a positive inotropic effect in the dog, but not in the
cat.
Our results lead us to question the validity of equating changes in dj* max with
dt
changes in indices of performance of the heart as a pump under abnormal conditions
and in the assessment of inotropic agents.
S U H M A R Y
In view of the recent work on isolated cardiac muscle which
has shown that situations can occur in which the force and velocity
of contraction are changed in different directions, we have
questioned the usefulness of the search for a single index of
contractility related to the rate of rise of tension, a trend
which dominates studies of the heart in vivo. We have attempted
to show, in the heart in vivo, that situations do occur in which
the duration of contraction can determine the force of contraction
or in which force and velocity of contraction are changed in
different directions such that purely a change in the velocity
dependant aspects of contraction would not describe the inotropic
intervention.
Dog hearts have been prepared in situ so that heart rate (IIR),
left ventricular end diastolic pressure (LVEDP) and mean aortic
pressure (MAP) can be controlled separately during computation of
left ventricular ciP max and external stroke work (SW). Progressive
dt
increases in HR consistently raised dP_ max over a wide range, and
dt
consistently lowered SW except at low rates. Progressive increases
in LVEDP or MAP consistently raised both d_P max and SW. Infusion
dt
of noradrenaline consistently raised both dP_ max and SW, except at
dt
very high HR when only dj? max was consistently raised.
dt
Wo have investigated the haemodynamic effects of sotalol and
bretylium which have been reported to increase the force of contraction
Summary Continued:
by prolonging the duration of the contraction in isolated
cardiac muscle. We were unable to show that these drugs
produced divergent effects on d_P max and SW, although sotalol
dt
but not bretylium did prolong the duration of contraction.
We also investigated the cardiovascular effects of prosta¬
glandins C and E and found that both prostaglandins have a
positive inotropic effect in the dog, but not in the cat.
Our results lead us to question the validity of equating
changes in dP_ max with changes in indices of performance of
dt
the heart as a pump under abnormal conditions and in the
assessment of inotropic agents.
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INTRODUCTI 0 N
The effect of initial muscle length on the contraction of
the muscle is part of the fundamental background of muscle
physiology, and was first observed in skeletal muscle (Blix 1895).
The effect was confirmed in cardiac muscle by Frank (1895).
Using an isolated frog heart preparation which was contracting
isometrically, he showed that ''the peaks of the isometric curves
rise with increasing initial tension (filling)''. Although Frank
implies that end diastolic filling is the important factor, his
experiments were designed to measure only end diastolic tension,
and so it remained for Starling and his co-workers to specify
initial muscle length as the prime determinant of work done during
the following contraction. Starling (1918) showed in a dog heart-
lung preparation that with a moderate increase in inflow or
arterial resistance there was an increase in end diastolic muscle
length, but little or no rise in end diastolic pressure. Yet
stroke work (when aortic pressure was raised) and stroke volume
(when inflow was increased) were invariably increased. These
findings led Starling to state that 'the Law of the heart is thus
the same as the Law of muscular tissue, generally that the energy
of contraction however measured, is a function of the length of
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the muscle fibre. This length-energy relationship dominated the
field of cardiac function for the next thirty years, in which time
the inability of Starling's Law to explain the cardiovascular
phenomena associated with exercise led Hamilton (1955) and Rushmer
2
(1955) nnd other workers to question Its importance in the
intact animal. Starling himself, however, had considered
that the length-energy relationship was not the sole mechanism
responsible for the increased output in exercise. ''But the
effect of throwing this organ (heart) into the circle of control
by the central nervous system is that it is kept in rest or
act iv ity in ai equable condition and the dilatation, which was so
marked a condition of its reaction when isolated, is reduced
to such small dimensions in the heart reined in and controlled
by the cardiac centres, and helped by the correlated changes
in other organs, that it becomes imperceptible in the intact
animal, and is not revealed for instance, by any radiographic
study of the heart during exercise.'' (Starling 1920).
The paradox of a decrease in end diastolic volume (EDV) and
an increase in stroke work (SW) observed in exercise was
explained by Sarnoff & Berglund (1954). They introduced the
concept of a family of ventricular function curves but attributed
the idea to J.W. Dow. In their experiments, mean atrial pressure
was used as an indication of the EDV of the ventricle and external
SW (measured by multiplying stroke volume by mean arterial pressure)
as an index of the force of contraction of the left ventricle.
They established the ventricular function curve which expresses
the increases in external SW associated with increments in initial
muscle length according to Starlings Law, and showed that when
the contractile state of the heart is altered, bv injection of
adrenaline, the ventricular function curve is shifted to the left,
i.e. an increase in the contractile state of the heart is
associated with an increase in external SW at any given muscle
length. This concept explained why in exercise Starling's
Law still applied although SW was increased while filling
pressure remained the same or decreased. In later experiments
Sarnoff et al (1960a) used the concept of a family of ventri¬
cular function curves to quantitate the inotropic response of
the heart to cardiac sympathetic nerve stimulation. In these
experiments an increase in ventricular contractility was defined
as an increase in external SW at any given left ventricular
end diastolic pressure (LVEDP). These experiments have been
criticised, because it has been shown that changes in heart rate
and in mean arterial pressure (MAP) can also influence the
external SW.
An increase in the amplitude of contraction resulting from
an increase in the frequency of contraction was first noted by
Bowditch (1871) in the frog heart. This effect was confirmed in
the intact animal by Rosenblueth et al (195^1i)and by Sarnoff et
al (1960b). Rosenblueth et al showed, that in the perfused
dog heart contracting isometrically, when the frequency of
stimulation was increased, the ventricular contractions gradually
increased to become stronger than the control contractions. The
return to the control rate produced a gradual decline of the-
contract Lon amplitude to the original level. The existence of
this staircase effect, as it has become known, necessitates the
control of heart rate in studies on the quantification of
myocardial contractility.
Two distinct mechanisms by which a change in MAT can alter
the amount of work done in a contraction have been reported.
From the mechanical properties of muscle, one would expect that
the work performed in a contraction is governed partly by the
resistance to shortening (afterload) that is offered by the
system in which the muscle is working. External work must
be zero both when external resistance is zero and when it is
too great for shortening, with a maximum in between. Changes
in afterload can, therefore, produce either a decrease, if the
afterload is increased above the optimal one, or an increase
in the work performed in a contraction from a given muscle
length. In the intact animal, MAP approximates to the afterload
in an isolated muscle; changes in MAP may therefore produce
changes in the SW perfomed from a given EDV even although
myocardial contractility is constant. This effect was confirmed
in the cat heart in situ by Sonnenblick and Downing (1963). In
their preparation, the heart was paced and reflex activity was
abolished by ligation of the brachiocephalic artery. They
showed that at a given LVEDP, stroke volume was not affected
appreciably by changes in MAP over a wide physiological range.
It follows that at any given LVEDP, SW is a function of M\P.
The other effect which has been reported when MAP is changed
is that described as the Anrep effect. Anrep (19L2) and Knowlcton
and Starling (1912) first observed that if the aortic pressure of
the heart-lung preparation was increased suddenly, the diastolic
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volume first rose, resulting in an increased output. After a
number of beats the same output was maintained although the
diastolic volume had returned to its control level. A gradual
increase in myocardial contractility must have occurred. The
increased contractility persists as long as the aortic pressure
remains raised. The mechanism responsible for the Attrep effect
is not known. The Anrep effect is to be distinguished from the
other mechanism described by which an increase in MAP may produce
an increase in SW at constant LVEDP, but which need not imply a
change in the contractile state of the heart.
As variables, such as heart rate and MAij have been shown to
affect the energy of contraction, the ventricular function curve
cannot be regarded as a unique representation of the contractile
state of the heart. Although Sarnoff (1960b), himself investi¬
gated the effects of MAP on SW, he used external SW, as an iiiidex
of myocardial contractility in experiments in which MAP was subject
to change. Under these conditions, one cannot assess to what
extent a change in SW was due to a change in MAP, or to a direct
effect of adrenaline on the contractile elements of the heart.
These limitations in the use of SW to describe changes in the
contractile state of the heart led to a search for an index of
contractility which was independent of changes in In art rate,
LVEDP and MAP.
Around the same time, it was realised that a more precise
definition of the nature of cardiac contractility, in terms of
the concepts developed by A.V. Hill for skeletal muscle, was
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necessary as a basis for the appreciation of cardiac dynamics:
particularly in order to formulate in fundamental terms changes
in myocardial contractility and the mechanisms by which these
changes were accomplished. The essence of the concepts
developed by A. V. Hill (1938) for skeletal muscle is that a
muscle behaves as if it were composed of three components.
1. An active contractile element (CE) which can develop tension
or shorten according to a particular force-velocity relation¬
ship.
2. A series elastic element mechanically in series with the
contractile element.
3. A parallel elastic element mechanically in parallel with
the CE.
When the CE is actively shortening or developing force, the
muscle is said to be in the active state. Using this model, it
is clear that two fundamental parameters determine the mechanical
response of the muscle. One relating directly to force develop¬
ment and the other relating to the velocity of shortening. Under
any given circumstance, the velocity of shortening of the CE is
uniquely determined by the tension in the muscle. As the tension
is increased, the velocity of shortening is decreased, according
to the equation formulated by Hill.
(P + a)(v + b) = (Po + a)b = Constant
where P is the load lifted: v is the velocity of shortening:
Po is the maximum isometric tension: a & b are constants.
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The graph of velocity of shortening as a function of
tension is generally described as being hyperbolic for skeletal
muscle, and it intersects the axes at finite values of force and
veloctiy. The unique properties of the force-velocity relation
hold only under conditions where P and V are measured at a
constant Po i.e. at a muscle length where Po is not length
dependant and the active state intensity is not changing with
time. For this reason the force veloctiy relation is most
easily studied and is most useful for quantification of the CE
in skeletal muscle in which Po is constant when the muscle is
maintained in a steady state of full activity by tetanic
stimulation. In a tetanic isometric contraction, the tension
developed, Po, depends only on the maximum intensity of the
active state and not on the duration of the active state or the
intrinsic speed of the muscle. The force intercept of the
instantaneous force-velocity curve, therefore, corresponds to
the intensity of the active state, which provides a useful index
of the degree of activation of the CE at that instant. Similarly
the intercept on the velocity axis will provide a measure of the
maximum speed per unit muscle length at which the muscle shortens
under zero load. An inotropic change can therefore be defined as
a change in the force-velocity relationship of the muscle, when
the measurements of force and velocity are made at constant CE
length and time after excitation. It has been shown, however,
that in cardiac muscle, it is not possible in an afterloaded isotonic
contraction to measure the force-velocity relationship of the CE
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within the necessary conditions of constant CE length and time
after excitation (Brady 1968). This is because skeletal muscle
and cardiac muscle differ in four important respects..
1. Cardiac muscle cannot be tetanized. Therefore, Po , the
maximum force generating capacity of the muscle cannot be
found directly, but only by extrapolation of the force-
velocity curve. This is not accurate, particularly since
peak isometric twitch tension in cardiac muscle can be
modified greatly by factors such as frequency of contraction
and humoral agents.
2. In cardiac muscle the development of contractile activity is
relatively slow compared with skeletal muscle. In afterloaded
contractions , therefore, the instantaneous force-velocity
relation measured at the time each load is lifted is different
from that at any other load, and the velocity at which high
loads are lifted may not be maximal intially.
3. In skeletal muscle a range of muscle lengths near body length
can be selected for study in which the tetanic isometric force
developed is relatively constant. Thus varying degrees of
internal shortening occurring with different afterloads do
not appreciably alter the driving force of the contraction.
In cardiac muscle, changes in muscle lengths close to body
length cause changes in the peak isometric twitch tension.
4. At this range of muscle lengths little resting tension exists
in skeletal muscle. The load lifted by the CE is constant
and is thus not affected by the transfer of resting tension to
9
Che CE as muscle shortening occurs. In cardiac muscle
there is a considerable resting tension at muscle lengths
where maximum tension is developed, and therefore, the
load on the CE, as the muscle shortens is not constant.
The force-velocity relations in cardiac muscle abound
with uncertainties. Since Po becomes a time dependant function
in cardiac muscle, the available energy in the system at any
moment is time dependent. Such a system is no longer a unique
function of force and velocity. Although the basic processes
of actomyosin association in cardiac and skeletal muscles are
similar: the dependance on time and length, and the influence
of resting tension on cardiac CE force-velocity curves makes
the formulation of the basic principles governing cardiac
mechanics very difficult using classical techniques developed
for skeletal muscle. Furthermore the concept of active state
which was developed for skeletal muscle loses much of its
advantage when applied to cardiac muscle. In skeletal muscle,
the intensity of the active state reaches a plateau which can
be maintained by repetitive stimulation. Various properties
of the muscle are studied in the state of full activity and it
is possible to ascribe changes in twitch tension either to a
change in the duration or the intensity of the fully active
state. In the case of cardiac muscle there is not a plateau
of activity and so it is less meaningful to consider any property
of heart muscle in terms of fully active state.
Such analysis, however, has been applied to cardiac muscle
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in an attempt to define inotropic changes in terms of the
fundamental properties of muscle. Abott and Mommaerts (1959)
in the first attempt to analyse some of the fundamental
mechanical characteristics of cardiac contractility, used
the force-velocity relationship in cat papillary muscle to
show that the positive inotropic effect, produced by an
increase in frequency of contraction, was associated with an
increase in the velocity of contraction as well as an increase
in the force of contraction. These studies were extended by
Sonnenblick (1962) who extrapolated the force-velocity curves
and related inotropic changes to changes in the maximum
velocity of shortening, Vmax, the intercept on the velocity
axis. He reported that an increase in initial muscle length
caused an increase in rate of development of force# an increased
Po, but no change in Vmax. He concluded that, since Vmax was
independent of changes in initial muscle length, Vmax could be
used to quantitate the contractile state of the heart. This
idea was further supported by his results that inotropic inter¬
ventions, such as increased frequency of contraction or the
addition of noradrenaline was characterised by an increase in
Vmax with a variable effect on Po. The force-velocity curves
in both these studies were plotted from the initial velocity
of shortening in contractions lifting various after loads.
For the reasons stated above, ideally the relation of force to
velocity should be determined at a given time after excitation,
it is possible, therefore, that changes in the shape of Sontien-
blick's curves could be consistent with changes in the time course
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of the contraction.
The results of these first experiments in cardiac muscle
led to the realisation that the rate of development of force
as well as the force of contraction required consideration
in connection with concepts of contractility. Although the
experimental difficulties involved in measuring Vmax negate
its value as a measurement of contractile element velocity,
it does reflect changes in the rate of development of tension
and as such is useful. In the intact heart, force in the
left ventricular wall is related to left ventricular pressure,
P, though ventricular dimensions. Hefner et al (1962) showed
experimentally that
F = Pa. equation 1.
where F = Force tending to pull the ventricle into two halves
P = left ventricular pressure.
a = cross sectional area of the cavity in the plane of
division of the ventricle into two halves.
The rate of development of force can, therefore, be related
to the rate of development of pressure in the ventricle, as
follows, differentiating equation 1 with respect to time.
dF dP da
„
— = — a + — p
dt dt dt
If the analysis is confined to the isovolumlc contraction period,
and the assumption is made that the contraction is isometric,
i.e. da






The maximum rate of rise of ventricular pressure
(dp max) during the isovolum.ic phase can be used as an
(dt )
indirect measure of the maximum rate of ventricular work.
During an isovolumic contraction, as the CE shortens at a
particular velocity, it stretches the series elastic element.
The rate of development of pressure in the ventricle is,
therefore determined by the velocity of contraction of the CE,
the elasticity of the series elastic element and the size of
the ventricle. Since no inotropic interventions have been
shown to alter the properties of the series elastic element,
it can usually be assumed that d_P max can be used as an index
dt
of a change in the velocity of the CE. An increase in initial
muscle length increases clF (Sonnenblick 1962). An increase
dt
in EDV induces an increase in initial muscle length and an increase
in a, in equation 2. The effect of an increase in heart size
on d_P max will, therefore, depend on the balance between the
dt
increase in dF_ and the increase in a. If the changes do not
dt
balance, dP max will be sensitive to changes in heart size,
dt
dP max ought to be insensitive to changes in MAP, if it is
dt
measured within the isovolumic phase.
As early as 1914, Wiggers showed that adrenaline increased
the mean rate of rise of pressure in the ventricle. He also
reports that when end diastolic filling pressure was raised by
increasing venous return to the heart, the rate of rise of
pressure was also increased. Since this report, there has
been much disagreement in the literature on the question of
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the independence of d_P_ max on LVEDP and MAP. Reeves et al
dt
( 1960) showed that in the anaesthetized dog, changes in d_P max,
dt
induced by noradrenaline had a significant correlation with
changes in peak ventricular pressure and changes in contractile
force measured with a strain gauge arch. d_P max also varied
dt
with changes in ventricular end diastolic pressure. In these
experiments, MAP was allowed to change freely. It has since
been shown that dP max does vary with changes in MAP (Clancy
dt
et al 1968). For this reason, one cannot conclude from these
experiments that dj> max is independent of LVEDP. Wal lace( 1963),
dt
however, observed the effect of changing either HR, MAP or
LVEDP on d_P max while the other two variables were held constant,
dt
He concluded that an increase in LVEDP did produce an increase
in d_P max.
dt
These results impose the same limitations on d_P max when
dt
it is used as an index of myocardial contractility as are imposed
on SW. In spite of these limitations, clP max has become a popular
dt
index of contractility, particularly as it is very sensitive to
the inotropic effect of catecholamines. The effect of catechola¬
mines on dP^ max was first established by Gleason and Braunwald
dt
(1962) in human subjects. Large increases in d_P max were recorded
dt
in response to intravenous injections of isoprenaLLne and
noradrenaline. These results were confirmed by Franklin et al
(1962) who showed that in anaesthetized dogs, marked increases




In a sense, it was unfortunate that the inotropic
effect of catecholamines is characterized primarily by such
a marked effect on the rate of contraction, because this led
to the idea that inotropic changes were determined by a single
factor, the change in Vmax. This in turn led to a search
for a single index of contractility occurring in the isometric
phase of contraction which reflected a change in Vmax.
Siegel and Sonnenblick (1963) introduced the index dPJIIT :
dt I
where IIT is a constant fraction of the integrated systolic
isometric tension based on the time to dP_ max. Although
dt
dP max and IIT both increase as EDV is increased, the ratio
dt
dPlIIT was claimed to be independent of changes in muscle
dt!
length. In a later study changes in this index were compared
with changes in the ventricular function curve (Siegel et al
1964). Sympathetic nerve stimulation via the stellate ganglion
at constant 1IR, produced a marked shift to the left in the
ventricular function curve. This was associated with an increase
in dP max and an increase in IIT, but because the increase in
dt
dP was proportionally greater than the increase in IIT, an
dt
increase in the ratio d_P IIT also occurred. This increase
dt
in dPIIIT was also independent of changes in LVEDP. The effect
dt I
of a small increase in HR was also observed. No detectable
change in the ventricular function curve was obtained but because
there was an increase in cIP max with virtually no change in IIT,
dt
the index dP IIIT increased. From these results, it was concluded
dt I
that changes in contractility were characterized by a change in
15
the velocity dependant aspects of contraction which may or may
not be associated with changes in the force of contraction.
The ratio dP11IT was claimed to be a more reliable index of
dt I
myocardial contractility than the ventricular function curve,
because, a) dPIIIT is independent of changes in LVEDP and
dt I
thus enables distinction between the Starling mechanism and
true inotropic changes.
b) dlP ITT reflects changes in the velocity of contraction
dt
better than a ventricular function curve.
Attempts have also been made to derive force-velocity
relations from the isovolumic phase of contraction in the intact
heart. In addition to the theoretical objections already
described, the measurement of both the velocity and the load in
the intact heart requires the consideration of several additional
factors that are difficult to quantitate precisely. For example;
the assumption of uniform wall thickness and that all fibres run
circumferentially and contract synchronously, the use of a
spherical model for the left ventricle, and the assumption that
absolute initial volume of the ventricle may be derived from the
end diastolic pressure in the ventricle by using a pressure volume
curve. The velocity of the CE is calculated by assuming a two
compartment model of heart muscle, in which the CE, as it shortens
during the isovolumic contraction of the muscle, stretches a
series elastic component. The velocity of the series elastic
element extension (d_l) and therefore the velocity of CE shortening
(dt )
is considered to be directly related to the rate of force
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development: (dF) and inversely related to the stiffness of the
(dt)
series elastic e lenient. (dF )
(dl)
i.e. dl_ dF /dt equation 3.
dt dP/dl
The stress-strain relation of the series elastic element,
measured experimentally in isolated muscle can be described by
the equation.
dF K P + C
dl
Since dj? _ dF/dt as shown previously
dt a
equation 3 becomes:
dl _ dP a
dt dt equation 4.
KP + C
If there is no change in heart size: equation 4 approximates to:
Vce = dP/dt
KP
where Vce is the velocity of CE shortening.
Covell et al (1966) produced force-velocity curves in the intact
dog heart by plotting a measure of Vce similar to that derived
above against myocardial wall tension. Wall tension was calculated
from the formula T = Pri where P = transmural pressure, ri = internal
2 h
radius of the ventricle and h = wall thickness. The relative sen-
it ivity of the force-velocity relationship was compared with that of
the ventricular function curve by exerting small inotropic interven¬
tions. Noradrenaline infusion always increased Po and maximum Vce
(obtained by extrapolation of the curve to zero load) and d£ max.
dt
1 7
Tn three out of seven experiments these effects were accompanied
by an increase in SW measured at constant LVEDP and MAP.
Similarly an increase in IIR produced an increase in Vee although Po
was increased only very slightly and SW was unchanged. The
inconsistency of the effect of noradrenaline and the lack of
effect of a change in HR on SW led the authors to conclude that
the ventricular function curve was unable to assess alterations
in the contractile state of the heart which were reflected
primarily by a change in the velocity of contraction, and that
the ventricular function curve was also less sensitive than the
force-velocity relation in detecting changes in the force of
contraction.
In some studies, difficulties with extrapolation to zero
load to obtain maximum Vce have been avoided by selecting certain
points on the curve relating d_P I P versus tension or pressure
dt I
(Mirsky 1971). Variations in experimental approach and the
assignment of different terms to these indices has led to
confusion but basically the two most widely used are max (d_P I P)
(at I )
and d£ max I L> where P is either total or developed pressure
dt I
in the ventricle; sometimes the factor K is also introduced.
These derivatives of dP max are being widely used in clinical
dt
situations to assess myocardial contractility, but as Noble (1972)
has pointed out, none of these indices are valid under all
circumstances and in view of the assumptions which must be made in
their measurement, the accuracy of these derivatives in assessing
a change in maximum velocity of the CE is highly questionable.
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In view oi" the theoretical and practical problems involved
in the measurement in the intact heart of Vmax and the other
derived indices, it is doubtful if these indices offer much
advantage over the basic measurement of dP max, from which they
dt
are derived. For this reason, d_P max is used most often as an
dt
index of contractility. Furnival et al (1970) emphasised the
usefulness of cfP max as a sensitive and quantitative index of
dt
inotropic changes in the left ventricle. In their experiments
a right heart bypass preparation was established in open chest
dogs in which it was possible to hold constant LVEDP by varying
the output of the bypass pump and MAP by adjusting a screw clamp
on the descending aorta. Isoprenaline was infused and its effect
on free HR was observed. Changes in dJP max were then measured,
dt
during the infusion at constant HR, MAP & LVEDP. The changes in
dP max were compared with the changes in free IIR, which were used
dt
as an index of the changes in catecholamine concentration at the
SA node. It was shown that chanjpsindJP max were proportional to
dt
the changes in HR, which followed stepwise increments in the
rate of infusion of isoprenaline. The authors concluded that
the changes in dP max were also proportional to the concomitant
dt
inotropic changes, and that d_P max was thus a quantitative index
dt
of inotropic changes. d_P max was also compared with SW at
dt
constant LVEDP, during the infusion of isoprenaline. Under
conditions of constant HR A MAP they found that changes in SW
were not consistent with the changes in dP max. SW was,
dt
therefore, said to be an unreliable guide to changes in
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myocardial contractility.
Furnival ct al stressed the conclusion that dP_ max is
dt
the best quantitative index of the actionofan inotropic drug
on myocardial performance. Implicit in this statement, is
the assumption that only one mechanism is involved in controlling
contractility, namely the rate of development of tension.
Although this is the mechanism by which catecholamines produce
their inotropic effect on the heart, it is not the sole
mechanism by which contractility can be increased. The
mechanical properties of muscle deny the general application
of a single index of myocardial contractility since three
fundamental relationships provide a complete description of
the contractile component;
1. The length-tension curve of active muscle (which is the
basis of Starling's Law).
2. The force-velocity curve.
3. The time course of the contraction.
Four variables, the tension in the muscle, the velocity
of shortening, the muscle length, and time after excitation,
are involved all of which may change simultaneously during a
contraction. It has been proposed that a change in myocardial
contractility can be defined as a change in the performance of
the heart which results from a change in the relationship among
these four variables during a contraction, (blinks and Koch-
Weser 1963). This definition does not provide any simple way
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of measuring changes in contractility: but it does provide
an objective criterion for deciding whether a given change
should or should not be regarded as constituting a change in
myocardial contractility. Under this definition, only the
effects of changes in the fundamental properties of the CE
are considered to represent changes in contractility, while
changes in performance arising solely from conditions outside
the heart are not. For example, a change in the amount of work
done in the contraction caused by a change in preload (LVEDP)
or in the resistance to ejection (MAP) does not reflect a change
in contractility. The relations among the four variables during
a contraction can be influenced in various ways, and a thorough
characterisation of a change in myocardial contractility requires
a full description of the changes.
An increase in myocardial contractility will be manifested
by an increase in the strength of contraction. Depending upon
the nature of the experiment, this increase in the strength of
contraction will appear either as an increase in the peak tension
developed or an increase in the amount of shortening in a
contraction or both. There are two basic mechanisms by which the
strength of contraction can be modified in heart muscle, under
conditions of constant initial muscle length and resistance to
shortening.
1. A change in the degree of activation of the muscle: which is
reflected by a change in the force-velocity relationship of
the muscle. In the intact heart, this effect is reflected by
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an Increase iti the rate of development of pressure in the
ventricle d_P. An increase in the degree of activation will
dt
normally cause an increase in the peak tension developed
unless it is offset by a big decrease in the duration of
contract ion.
2. A change in the duration of contraction. Under controlled
conditions a change in the time to peak tension of an isometric
contraction^ or a change in the total duration of contraction
can be regarded as signifying a change in the duration of
activity of the CE. By increasing the time available for
tension to develop or for shortening to occur, an increase in
the duration of contraction may produce a positive inotropic
effect.
It is a dangerous oversimplification to describe a given
change in the performance of the heart only as an increase or a
decrease in contractility. The current emphasis of looking for
a single index of contractility may hamper progress in defining
inotropic changes in terms of fundamental processes and ultimately
in terms of the underlying cellular and biochemical mechanisms.
Attempts are being made in isolated muscle studies to relate
inotropic effects more closely to their cellular mode of action
and the first step towards this has been the classification of
inotropic drugs according to their effects on the time course
of the isometric contraction as well as their effect on the rate
of development of tension and peak tension (Reiter 1972).
Although physiological and pharmacological interventions such as
I
increased HR, catecholamines and digitales glycosides produce
their inotropic effect by increasing the degree of activation
there has been an increasing number of reports from isolated
muscle studies about drugs which induce a positive inotropic
effect by prolongation of the contraction. In the intact
heart, changes in the duration of contraction would not be
expected to induce changes in dP^ max: although they might be
dt
reflected by changes in SW. In view of this and also of the
increasing trend for clinicians to use changes in dP_ max as
dt
an index of contractility although such changes may be unrelated
to changes in output of the heart, we decided to study the
action of certain drugs and physiological interventions on
various indices of contractility to show whether or not these
drugs could be classified into groups by their differential
action on the parameters studied. Most of the drugs studied
were those which had been shown in isolated muscle studies
to produce an effect on the duration of contraction. As a
change in the duration of the contraction is associated with a
change in electrical activity of the myocardium, a brief
description of the cardiac action potential seems appropriate.
In contrast to the very short duration of the action
potential in nerve and skeletal muscle the cardiac action
potential can be 100-500 milliseconds long ? depending on the
type of heart muscle. Although the eiec trical properties of
cardiac muscle are similar to those of nerve and skeletal muscle
in that the action potential is a result of a sequence of change
2 3
Ln membrane ionic permeabilities, with different ions carrying
charges into and out of the cells, the details of the ionic
currents in cardiac muscle are not fully understood. This is
partly a result of the practical difficulties involved in
applying the voltage clamp technique to cardiac muscle and
partly because of the greater complexity of the repolarisation
process in cardiac muscle. Upon depolarisation to threshold
the early inward current is carried by sodium ions, flowing
down their electrochemical gradient as a result of a large
increase in membrane perm eability to sodium ions which arises
from the depolarisation. These changes can be described by
the same general formulation devised by Hodgktnand Huxley for
squid axon. The magnitude of this current is a signoidal
function of the resting membrane potential value. Reuter (1968)
claims that the calcium ions which enter the muscle fibre upon
depolarisation also play a role as charge carriers, but the
existanceand the relative importance of this current is
controversial. The early inward current of sodium ions is
inactivated at two rates, most of it being inactivated within
10 ms, but there is evidence that a component of the sodium
inactivation requires about 100 ms to occur. This slow
inactivation contributes to the maintenance of depolarisation
during the plateau of the action potential. The potassium
currents responsible for repolarisation are quite complex.
Noble and Tsien ( 1969) have postulated the existence of four
separate channels. Upon depolarisation to threshold, there is a
substantial fall in potassium conductance which helps to reinforce
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the depolarising inward sodium current and which also helps to
maintain depolari.sati.on during the plateau. Two additional
potassium channels, ix^ and ix?, are postulated. These are
not pure potassium channels as other ions have been found to pass
through them. The channel ix^ is activated in the range of
potentials at which the plateau occurs and this time dependant
increase in potasium current may be the important outward
current in repolarisation from the plateau to the resting
membrane potential. This potassium current is variable and
has been shown to depend on action potential duration. IX2
is too slow to be involved in the normal action potential.
The fourth potassium channel is associated with the decreased
conductance which occurs after repolarisation and which constitutes
the basis of the pacemaker potential.
The multiplicity of currents involved in the cardiac action
potential is important not only because of their implications
regarding cardiac excitability, but because of the correlation
of ionic movements with the contractile activity of the heart.
The influx of sodium ions which occurs upon depolarisation of
the cardiac cell membrane is accompanied by an influx of calcium
++ ++
(Ca ) ions. The Ca influx is crucial to the initiation and
maintninnnce of the contraction. As the concentration of free
- 7 | |
calcium in the cell exceeds 10 M, Ca binds to the protein
troponin and by an unknown mechanism, removes the troponin
inhibition of bridge formation between actin and myosin.
Upon repolarisation Ca is removed from the myofilaments into
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the sarcoplasmic reticulum by an active transport mechanism
until the concentration is below the activation threshold
concentration of 10 , and the muscle relaxes. The
duration of the action potential is largely determined by
the duration of the plateau after depolarisation. The
duration of the plateau, as described previously is deter¬
mined by the relative ionic conductances of potassium (gk)
and sodium, and it is particularly sensitive to gk. A
reduced gk will prolong the duration of the plateau, thereby
| I
prolonging the influx of Ca and the duration of the
contract ion.
The influence of the duration of the action potential
on the strength of the contraction is seen particularly
in studies on the staircase phenomenon. In frog ventricle,
Niedergerke (1956) showed that repetitive stimulation of a
previously resting heart produced a progressive increase in
contractile tension. But, when this experiment was repeated
| j,
in a Ca rich solution, the first contraction was the largest
and successive contractions dimiiidnl in height. This negative
staircase was associated with loss of the plateau and reduction in
the duration of the action potential and in time to peak tension
as stimulation proceeded. Niedergerke concluded that there were
two opposing processes influencing contractility in the staircase
phenomenon, one facilitatory and the other inhibitory. Under the
experimental condition of a high Ca^ ' concentration, in which the
strength of contraction was maximal, the inhibitory effect of a
shortening in the duration of contraction was observed.
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Also supporting a direct relation between action potential and
tension, Kavaler (1959) extended the duration of the action
potential in sheep ventricular muscle strips to two seconds,
by sustaining the plateau potential with an applied current.
He observed that tension was maintained throughout the duration of
the plateau and relaxation occured only when the muscle fibres
were allowed to repolarise. These observations were extended by
Antoni et al (1969), who compared the responses of frog and
mammalian myocardium to changes in the action potential duration,
induced by constant current pulses. Prolongation of the
contraction produced an increase in peak tension of the
corresponding contraction only by increasing the time to peak
tension. The amplitude of the following contractions, however,
initiated by normal action potentials were still increased and
were due to an increase in the rate of rise of tension. Five
to seven beats were necessary for the development of a steady
state. In frog myocardium, however, the contractile response
to alterations of the duration of the action potential were
limited to the corresponding contraction. The effects of changes
in duration of a single action potential on subsequent beats in
mammalian myocardium was confirmed by Wood et al ( 1969).
In order to explain their results Antonii and Wood both
-t-f
postulated the existence of an intracellular store of Ca ions
associated with the transverse tubules and the sarcoplasmic
reticulum. The initial effect of a change in action potential
duration on the corresponding contraction is postulated to result
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++
from a change in the amount of Ca entering the cell during that
++
action potential. The increased Ca influx, however, also
-j—f-
increases the size of the intracellular stores of Ca available
for release by subsequent action potentials. Frog myocardium, in
which the transverse tubule -sarcoplasmic reticulum is very poorly
developed does not show the increased dT_ in subsequent beats.
++
Many experiments using radio active Ca to measure Ca influx
during depolarisation have shown that only a small fraction of
++
the activator Ca originates directly from the extracellular
space (Langer 1973). These and other studies on the binding
j j
of Ca ions by the sarcoplasmic reticulum support the hypothesis
| |
of an intracellular store of Ca ions, in mammalian hearts.
The duration of contraction is determined by the balance
|- |.
between the time course of Ca influx and the activity of the
"1—b
Ca sequestration system. An increase in frequency of
stimulation and catecholamines usually produce a positive inotropic
_|
effect because the increased rate of arrival of Ca at the
troponin sites more than compensates for the negative inotropic
effect of a decreased duration. Interventions which produce a
positive inotropic effect, based on prolongation of the contraction
have only comparatively recently been investigated. The action
of caffeine in this respect has been most closely studied.
Degubareff and Sleator (1965) using guinea pig atria showed that
the positive inotropic effect of caffeine was associated with an
increase in the duration of the action potential and in the
++
duration of the contraction, this effect being dependant on Ca
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concentration. These results were confirmed by Gibb (1967)
Caffeine was shown to prevent the effect of adrenaline on the
relaxation phase of the contract ion such that adrenaline in the
presence of caffeine, no longer abbreviated the contraction.
The effects of caffeine on force development in myocardium
are consistent with a dual action of caffeine on excitation-
contraction coupling as proposed by Blinks et al (1972).
In their experiments on kitten papillary muscle, caffeine not
only increased the duration of contraction but also increased
the maximal rate of tension development (dT max). Procaine
(dt )
antagonised the caffeine induced prolongation of duration of
tension development, but did not affect the initial rapid
increase in dTT max and peak tension. It was, therefore,
dt
proposed that caffeine increased the duration of contraction
|- |
by inhibiting Ca sequestration by the sarcoplasmic reticulum,
an action which is procaine sensitive: and also is capable of
*4—f~
inducing Ca release, which is procaine insensitive. These
concepts are supported by work done on isolated frog and rabbit
skeletal sarcoplasmic reticulum preparations. (Weber and Herz 196
_|
It was noted that caffeine produced a release of Ca from
reticulum preparations loaded with Ca^ and it also reduced the
H—1-
rate of Ca uptake by the sarcoplasmic reticulum.
High concentrations oftyramine, cevadinc, veratridine,
sotalol and bretylium are among the other agents recently
reported as having a slowing action on the relaxation phase of
contraction paralled by a characteristic prolong,at ion of the
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action potential. Although this action has only been reported
in isolated muscle, there has been some controversy over the
positive inotropic effect of sotalol and bretylium in vivo.
We decided to investigate the positive inotropic effect of
sotalol and bretylium in vivo to determine whether this action
maybe attributable in part to their effects on the duration of
the contraction.
Sotalol, 4'- (1- hydroxy-2-(isopropylamino)ethy1) meLhane
sulphonanilide He 1: formula
/ \ /CH3
CH3 • S0? • NH p CjH - CH2 • NH - CH^
is a beta adrenergic blocking drug. Three actions of sotalol
on myocardial contractility have been reported.
1. an indirect depression caused by blockade of the effect of
circulating catecholamines on the heart.
2. a direct negative inotropic effect.
3. a positive inotropic effect, produced by prolongation of the
contract ion .
Blinks (1967) observed that sotalol antagonised the
inotropic and chronotropic effect of catecholamines and in
very high concentrations also produced a direct depression of the
strength and frequency of contraction of the heart. Superim -
posed on this depression of contractility, sotalol had a stimulant
action on the strength of contraction in cat ventricular muscle
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but not atrial muscle. This positive inotropic effect was not
mediated via beta receptors in the heart since it was not
prevented by propmnalo1. (Kauma tn & Blinks 1967). The developed
-4
twitch tension was greatest in a concentration of 10 M sotalol.
At this concentration, sotalol slowed the terminal phase of
relaxation and a small amount of active tension, which tine
authors named an aftercontraction, persisted after each contraction.
The aftercontractions were associated with a marked prolongation
of the action potential (Kaumann and Olson 1968). With long exposure
to the drug, the duration of the action potential and the twitch plus
aftercontraction could be increased three to five fold from the
control. The effect of sotalol on the duration of contraction
was also investigated by Parmley et al (1972). Comparing
sotalol with propranalol on cat papillary muscle contracting
isometrically, they showed that sotalol, in a concentration of
-4 -3
10 M to 10 M, caused an increase in contractile force accom¬
panied by a prolongation of the contraction: whereas propranalol
at doses greater than 10 had a negative inotropic effect, and
caused shortening of the duration of the contraction. At a dose
-2
of 10 M, however, sotalol caused a marked depression of contractile
force. The positive inotropic effect of sotalol was unchanged in
reserpine pretreated muscles. A detailed examination of the effect
of sotalol on the electrophysiological properties of cardiac tissue
has been carried out by Strauss et al ( 1970), and Singh and Vnughan
Williams (1970). Strauss et al showed that sotalol., in doses up to5.10
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had no action on the resting membrane potential, on overshoot
amplitude and on the maximum rate of rise of the action potential
in dog parkinje and ventricular muscle fibres. Under conditions
of constant cycle length, sotalol in concentrations between 10 ^
-3
and 10 M, prolonged the duration of the action potential as a
result of lengthening of the plateau of the action potential
and particularly the terminal phase of repolarisation. These
results were confirmed by Singhand Vaughan Williams in cat
papillary muscle. They also reported that sotalol prolonged the
Q-Tc interval with no change in the P-R interval of the E.C.G.
recorded in anaesthetised guinea pig. This effect was, however,
associated with a slowing of the spontaneous heart rate. In the
intact heart, conflicting results have been reported. Hoffman
and Grupp (1969) noted that sotalol reduced ventricular contractile
force in both normal and reserpinised anaesthetised dogs,
indicating a direct negative inotropic effect. Puri and Bing
(1969), however, concluded that sotalol had no direct myocardial
depressant action and that the fall in dP max associated with a
dt
fall in IIR, was due to blockade of the action of circulating
catecholamines. Systolic time was prolonged and therefore
stroke output and stroke work remained unchanged. The lack of
a direct depressant action of sotalol was also noted in man
(Svedmyr et al 1970).
Brotylium tosylate is a quaternary benzyl ammonium salt:




The ability of bretylium to increase myocarial contractility
was first described by Boura cSr Green ( 1959) who introduced the
drug as a hypotensive agent. The basis for bretyHum's
hypotensive action was its ability to block the release of
noradrenaline from adrenergic nerve endings. It's blocking
action was preceded by an initial release of noradrenaline.
Subsequent studies confirmed a positive inotropic effect of
bretylium but disagreed about its importance and mechanism.
Gilmore & Siegel (1962) reported that, in the dog, bretylium
administration like cardiac sympathetic nerve stimulation
produced an increase in myocardial contractility which was
accompanied by an increase in the coronary venous catecholamine
levels. They concluded, therefore, that the myocardial effects,
of bretylium were entirely indirect and were due to the release
of endogenous catecholamines. Gaffney, however, was able to show
a small positive inotropic effect of bretylium on a dog heart-lung
preparation depleted of catecholamines by prior administration of
reserpine and in the complete cardiac denervated open chest dog.
(Gaffney 1961: Gaffney et al 1962). The positive chronotropic
effect of bretylium in the normal heart, which is associated with
release of noradrenaline, was reversed to a negative chronotropic
effect in the reserpinised heart. Gaffney concluded that in
addition to its indirect actions, bretylium had some direct
positive inotropic effect on heart muscle. This conclusion was
also drawn by Amsterdam et al (1970) who reported a positive
inotropic effect of bretylium on cat papillary muscle in the
presence of beta adrenergic blockade with propranalol. As the
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literature contained conflicting data on the question of
whether the inotropic effect of bretylium was due to catecholamine
release or a direct effect on the myocardium, Markis & Koch-
Weser (1971) re-examined the action of bretylium on isolated
mammalian myocardium. The positive inotropic effect of bretylium
on kitten papillary muscle, contracting isometrically, was accom¬
panied by an increase in the rate of development of tension with
a very slight decrease in the time to peak tension and no change
in the time to 907, relaxation. Noradrenaline, however, shortens
relaxation time and the duration of contraction is decreased.
On reserpine pretreated muscle, the positive inotropic effect was
much reduced but relaxation was slowed and consequently the
duration of contraction was increased. Bretylium was thus shown
to have a direct effect to slow relaxation. The failure of
bretylium to alter the relaxation time of normal myocardium
reflects the cancelling out of its direct effect on this parameter
of contraction and the opposing effect of released noradrenaline.
Although bretylium increases myocardial contractile force mainly
by the release of endogenous noradrenaline, the net inotropic
effect must reflect the interaction of this indirect action with
its direct action tending to prolong the duration of the contract¬
ion .
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M E T HODS
1. Control, of nnncsthesin, arterial blood i;as tensions , acid-
bnsc balance and tcmpernturc.
Mongrel dogs and cats were used as the experimental animal
species. Dogs wighing between 5 and 10 kg. were anaesthetized
by an intravenous injection of pentobarbitone sodium 30 mg/kg.
Cats weighing between 3.0 and 5.3 kg were anaesthetized by an
intraperitoneal injection of pentobarbitone sodium 40 mg/kg.
As changes in the depth of anaesthesia alter the parameters
which we were studying, a constant level of anaesthesia was
subsequently maintained by a continuous infusion of pentobarbitone
sodium, 6 mg/ml, into a femoral vein from a Palmer slow infusion
pump. The rate required was of the order 10-30 mls/liour for a
dog, depending upon the animals weight and the level of anaesthesia,
as indicated by muscle tone and the state of its corneal reflex.
The trachaea was cannulated and the animal ventilated with
1007, oxygen using a variable stroke Starling 'ideal' pump, running
at twenty strokes per minute. Changes in blood gas tension and
pH can directly affect the rhythm and the contractile state of the
heart. It was, therefore, necessary to maintain these parameters
within strict limits during the experiment. Throughout the experi¬
ment, samples of arterial blood were withdrawn at regular intervals
and p!l, Pco? and Po9 measured using a Radiometer BMS3 system.
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Arterial Pct>9 was kept as near possible to 28 torr in the cat
and 40 torr in the dog, by adjusting the stroke of the respiratory
pump. Plasma bicarbonate concentration was determined using the
nomogram of Siggaard-Anderson (1963) and corrected to 18 m>! in
the cat and 25m>l in the dog, when a base deficit had developed,
by an intravenous injection of an appropriate volume of 1M
sodium bicarbonate solution.
Rectal temperature was recorded from a thermistor probe
and was held near to 37°Cby a heating pad below the animal
and also when necessary an infra-red lamp above the animal,,
II. Operative procedure.
Incisions were made and bleeding points coagulated using a
Gimber veterinary diathermy unit. Aortic blood pressure was
recorded from a catheter inserted through the right common
carotid artery. Positive expiratory pressure ventilation was
applied and the chest opened through a mid-sternal split. The
heart was denervated by cutting the vagi and crushing the
sympathetic ansae. The pericardium was opened and when the
connective and fatty tissue around the aorta and the pulmonary
artery had been cleared away, an electromagnetic flow probe
(Statham Q Series) was placed around the ascending aorta. A
bipolar platinum electrode (20 mmlaig) was inserted into the
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right auricular appendage and the heart was paced, using 5 V
pulses of 5 ms duration at a frequency just faster than the
spontaneous rate. A purse string was sutured around the apex
of the left ventricle. The animal was heparinized (1000 u /kg)
and a metal cannula ( internal diameter 2.2 nun: length25mm )
with side holes was inserted through the apical dimple of the left
ventricle. Consolidated electrodynamic L223 transducers were
attached to the left ventricular and aortic pressure cannulae and
the signals amplified.
Ill Parameters measured
The dynamic response of the ventricular pressure recording
system was examined in order to be certain that the pressure pulse
contour which we recorded was an accurate reproduction of the
pressure changes in the ventricle. This analysis was not necessary
for the aortic pressure recording system as we were mainly
interested in the recording of mean arterial pressure. It is
assumed that any pressure function of time existing in the
circulation is a periodic function and as such constitutes what
is known as phasic oscillation. The simplest form of phasic
oscillation is the sine wave. By a Fourier analysis, any complex
phasic oscillation can be split down into a series of sine waves,
each being an arithmetic progression of frequencies. The general
equation for a Fourier series is
f(t) = A sin (wt + a) + B sin (2wt + b)... 4- Z sin (N'wt + n)
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each term being known as a harmonic. From a Fourier analysis,
the number ofbarmonies of significant amplitude necessary to
inscribe a pressure pulse indistinguishable from the original
can be calculated. Such analysis of typical ventricular pressure
pulses have indicated that it is necessary to record accurately
to the tenth harmonic of the pulse wave. Hansen (1950) has shown,
however, that in most cases the pressure pulse can be reproduced
with 95% accuracy by the first six harmonics.
In order to measure the frequency response of the ventricular
pressure recording system a square wave pressure change was applied
to the system by bursting an inflated balloon attached to the
transducer system. By applying the formulae derived by Hansen
and Warburg (1950) to the series of oscillations obtained upon
the square wave pressure change, the frequency response of the
system was obtained as follows
The damping factor B, was calculated from the equation
B equation 1.
where /\ is the difference between the natural logarithms of
consecutive overshoots on the same side of equilibrium.
The undamped natural frequncy is given by
f o equation 2.
2-rr t
D
where f is frequency is cycles/sec.
T is the period of one complete oscillation.
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From the amplitude-frequency curves for oscillation systems
with different degrees of damping (Hansen & Warburg 1950)
the value of YR (which is the ratio of the resonant frequency
to the undamped natural frequency) at which the amplitude
becomes either greater than 1.05 or less that 0.95 is found on
the line with the value of B obtained from equation 1. This
valu e of YR , multiplied by Fo obtained from equation 2, repre¬
sents the highest frequency which the system will reproduce
with better than 5% accuracy. Apart from the possible
amplitude distortion there is the possibility of phase
distortion. The phase difference angle is dependant upon
the relative frequency, Y, and the degree of damping. From
the graph relating relative phase difference time and the
influencing frequency for different degrees of damping (Hansen
and Warburg 1950), it can be seen that the relative phase
distortion is less the lower the degree of damping is. Our
system had a damping factor B =0.2 and so phase distortion was
practically negligible. The frequency response of the ventric¬
ular pressure recording system, obtained by this method, was flat
to 24 Hz. Since in our experiments the most rapid fundamental
frequency encountered was of the order of 4 Hz and Hansen states
that a pressure pulse can be reproduced with 95% accuracy by the
first six harmonics, the frequency response of this system is
sufficient for accurate reproduction of the ventricular pressure
pulse.
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The transducers were calibrated in a stepwise manner using
a mercury manometer. During each experiment, frequent checks
against a standard pressure, atmospheric pressure, allowed drift
to be recognised. The transducer connected to the ventricular
cannula was calibrated with the base of the heart as the reference
point.
Aortic pressure, left ventricular pressure and aortic flow
were recorded both on magnetic tape (Bell and Ilowell VR 3200)
and on light sensitive paper (Honeywell Visicorder). The
transducer amplifiers were also connected to the following
parallel analogue circuits.
I) An analogue differentiating circuit to derive LVdP.
dt
The circuit for derivation of LV dP is shown in Figure 1.
dt
In response to sine wave changes in the input voltage, the
output of the differentiator showed a 90° phase shift and tie re
was a linear relationship between the amplitude of the output
and the frequency of the input signal from 1 to 128HZ. The
recorded output was calibrated using a variable slope waveform
generator to provide an input to the differentiator. The output
of the generator was expressed in volts/sec. Since the output
amplitude of the left ventricular amplifier was known to be 2.3
volts output for 100 mm Hg, by comparing the differentiated ramp
amplitude and the dj^ left ventricular amplitude a calibration
dt
value for the differentiator was obtained. Frequent checks were
made to ensure that the differentiator remained calibrated at
5000 mm Hg s \
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Fig. 1 CIRCUIT DIAGRAM FOR OIFFERFNTWW
MKa 1 5Ma
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II) An EAL 380 analog computor Co derive LVEDP and external SW
beat by beat.
The external SW of the left ventricle is usually calculated
as the sum of two components, one the work done against pressure
and the other, the work done in imparting velocity Co the aortic
stream. The work done against pressure is given by the formula
W = / PdV
>
where t-t marks the beginning and end of systole: P is the
pressure of each increment of volume (dV) ejected.






where v is the velocity of each increment of weight (dM) ejected,
g is the gravity constant. Remington and Hamilton (1947)
calculated the velocity component of the external SW in dogs
and showed that at rest, it is of the order of 2% of the total
external work. As this function can be considered to be
insignificant in dogs at rest, it is usually omitted in the
calculation of external SW.
We calculated external SW according to the equation
i
t
SW - / F (I,VP - LVEDP) dt
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where F is the instantaneous aortic flow, LVP is the instantaneous
I
left ventricular pressure and t - t is the systolic phase of a
cardiac cycle. Most people calculate external SW, by making the
assumption that the whole of the stroke volume is ejected against
a constant pressure. SW can then be calculated using the mean values
of aortic pressure and stroke volume if the following assumptions
are made. The work done is equal to the force developed (F)
multiplied by the distance it moves (D).
i.e. W = F x D equation 3.
Since F = P x A and D = V
A
Where P is the pressure increase imparted to the blood by the heart,
V is the volume of blood ejected, and A is the cross sectional area
of the aorta. equation 3 becomes
W = PA x V
A
= PV
The calculation of external SW is therefore often approximated,
according to the formula - SW = (MAP - LVEDP) SV
The errors involved in this approximation are:
(1) MAP is less than the pressure during ejection, so that SW is
underestimated. This underestimate must increase if ejection time
becomes a smaller fraction of a cardiac cycle. This occurs if cat¬
echolamines are infused at a constant paced heart rate.
(2) Pressure and flow are out of phase such that flow is still
increasing when pressure is falling. Using a constant value of
pressure in the approximation will tend to overestimate SW since
because of the phase difference, pressure is proportionally smaller
for each value of flow.
In some experiments we also calculated SW, using the mean
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values of pressure and volume and compared these values with those
obtained using the integrated data. Both values of SW were
calibrated in niilli Joules (mJ), by using the appropriate conversion
factor.
The analogue computation necessary for the calculation of SW
and the reading of LVEDP is shown in Figure 2. After the inputs
have been scaled, LVEDP was obtained from the diastolic phase of the
LVP curve. The LVP record and the pulse responsible for the reading
of LVEDP were displayed on an oscilloscope so that the point in the
cardiac cycle at which LVEDP was being read, could be checked and
corrected, if necessary. LVEDP is continuously substracted from
the following LVP. LVP - LVEDP is then multiplied by the instan¬
taneous aortic flow, and the area under this curve is integrated to
i
provide a value of external SW.
Parralel logic was used to set the limits of each cardiac cycle
in the computation of SW, to read LVEDP, and to store the derived
parameters during each cardiac cycle. A comparator was used to
detect the point in the left ventricular pressure curve, at which
pressure begins to rise. When the LVP is less than the reference
voltage: i.e. when the heart is in diastole, a logic ' 1' level is
fed into and gate F. If the other input into and gate F is also
logic '1', the track/store amplifiers for LVEDP and SW will begin
to track. When the LVP begins to rise above the reference voltage,
the output of the comparator changes to logic 'o', causing the track/
store amplifiers to store the values of LVEDP and SW they had at the
instant of switching.
IC
Figure2.Theanaloguecomputationforthecal ulati nfSWandLVEDP. PPRarethepacemakerandre dingpulsesrespectively.
This occurs if there is a premature systole, in which case the
T/S continues to read the LVEDP for the previous beat. A
source of pulses is used to control the conditions of the other
and gates in the logic net. These pulses, of cycle Length
which is variable between 200 andlOOO ms, are used to provide
the pulses which drive the pacemaker in the right atrium. The
animal's HR can, therefore, be set by setting the cycle length of
the pulses. The duration of the pacemaker pulses (PP) was
controlled by a monostable, which was set at 5ms. For the
duration of the pacemaker pulse, the integrator is maintained
in a hold mode, so that the stimulus artifact which is detected
by the flowmeter is not integrated. The source of pacemaker
pulses also governs the control of a shift register, such that
each bit of the shift register will change state to a logic '1'
output, with a very short delay between the changing of each
bit. This delay circuit is necessary so that the integrator
can be reset by and gate E, a short time after the value of SW
has been read. When the output of register A is logic '1'
and the normal output of register B is logic 'o* the output of and
gate A is logic '1'. The output of and gate C is, therefore,
also logic '1'. If the heart is in diastole, as indicated by
the logic output of the comparator, the output of and gate F would
also be logic '1'. This logic ' 1' instructs the track/store
amplifiers to track the values of SW and LVEDP. The logic 11'
output of and gate F is, therefore, the pulse responsible for the
reading of LVEDP, this pulse (RP) occuring with a set delay after
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the pacemaker pulse. The shift register is cleared after a
delay governed by a monostable.
The pacemaker pulses were scaled so that when they were
recorded on magnetic tape, they were 1 volt in height above a
baseline of 0.5 volts. The three derived signals, d_P
dt
SW and LVEDP were also recorded on magnetic tape and on light-
sensitive paper. LVEDP and MAP were displayed throughout the
experiment on galvonometers : SW on a digital voltmeter and the
other parameters on a 4 channel oscilloscope. Calibration
signals representing known amounts of each parameter measured
were also recorded on the tape.
IV Data Analysis 1
The data recorded on magnetic tape were later analysed using
a PDP8 digital computer. The maximum voltage output of the tape
is 1.5 volts, but since the analogue to digital converter works
within the range 1 to 10 volts, each output on the tape was
multiplied five times before being fed into the analogue -
digital converter. The data analysis was carried out on a beat
to beat basis. Each parameter being measured had, therefore,
to have a static value. This had already been accomplished
for SW and LVEDP by the track/store amplifiers of the analogue
computer. Mean aortic pressure and cardiac output were obtained
by passing pulsatile aortic pressure and pulsatile aortic flow
signals respectively through averaging circuits before entering
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the digital, computer. An analogue peak height detector unit
was used to obtain positive d_P max from the record of dP.
dt dt
The maximum leakage from the capacitor through the resistor
which occurs before dP max is read is about TL of the value
dt
of d_P max. This is a consistant error and it was considered
dt
to be negligible in the reading of dj? max.
dt
The computer was programmed to recognise a change in voltage
in the pacemaker pulse channel, from 2.5 volts to 7.5 volts,
(i.e. one pacemaker pulse) as the beginning of each cardiac
cycle. Each of the other five channels were then read with
a delay of 6Gus between each reading. The total delay
involved in the reading of all the channels was 360 ms a
delay of this magnitude would not affect the readings over
each beat. The digital computer wras calibrated using the
calibration signals on the tape and the known values of each
calibration signal. The mean and standard error of mean (SEM)
of all the parameters were calculated over a sequence of ten
beats within each test. Before a print out of the mean values
of the parameters was obtained, the data from all ten beats was
displayed on a videoscope (Telephonix 40ID). If that particular
sequence of beats contained erroneous readings or if missed beats
had occurred, the data was rejected and another ten beats in the
test was analysed.
The reliability of the values obtained from the digital
computer was evaluated by frequent spot checks of the measurements
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recorded on the UV paper.
In those experiments, in which we wanted to observe an action
on free IIR, the HR was measured using the ECG. The ECG was
obtained through an electrode attached to the ventricular cannula
and an indifferent electrode. The R wave of the ECG was used to
trigger a ramp generator back to baseline, the amplitude of the
record produced being proportional to the R-R interval. The
device was calibrated by determining the amplitude equivalent
to one second.The free heart rates obtained using this method
were only recorded on UV paper. In the experiments, in which
we were looking for an effect on the duration of the electrical
and mechanical activity, we recorded the ECG at constant HR,
MAP and LVEDP during each test on magnetic tape.
Duration Parameters.
The durations of the mechanical and electrical activity in each
beat were measured by playing back the pulsatile ventricular
pressure, the pulsatile aortic pressure and the ECG records from
the tape onto a fast running UV paper. Three measurements were
made.
1. The time between the upstroke and the return to diastole
of the ventricular pressure curve, which was used as an
indication of the duration of the contraction.
2. The time from the onset of rise of the aortic pressure to
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the closure of the aortic valve, as indicated by the incisure
notch. This measurement was taken as an indication of the
duration of systole.
3. The time between the upstroke of the Q wave on the ECG trace
to the peak of the T wave.
V. Method of controlling or changing HR, MAP and LVEDP
As stated previously, the HR was controlled by pacing of the
right atrium. A change in HR was produced by adjusting the clock
of the analogue computer to produce pulses of the desired cycle
length.
In the cat MAP was held constant by compression of the
descending aorta against a cotton tape which had previously
been placed around it. LVEDP was held constant by injection of
a dextran solution or removal of blood.
Although this method was satisfactory in the cat, we found
that in the dog the compression of the aorta by a screw clip
did not provide sensitive enough control over MAP. For this
reason a different method of controlling MAP and LVEDP was used
in the dog. A compressed air blood pressure compensator was
used which consisted of an inverted conical flask, of volume
2 litres, attached to a compressed air supply inlet: a screw
clip which was used to regulate the air pressure in the
reservoir: and an anaeroid barometer for the measurement of
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the pressure in the reservoir. The blood pressure compensator
was attached to the animal via both femoral arteries. Care
was taken to maintain the resistance of the cannulae and the
connective tubing at the lowest possible value, by using the
largest bore cannulae possible. If the animals blood pressure
rose above the pressure set in the reservoir, blood would
move out of the animal down the pressure gradient, until the
pressure in the animal and the pressure in the reservoir were
equal. Similarly, if the animalfe BP fell below that in the
reservoir, blood would move in from the reservoir until the
pressure gradient was zero. In order to prevent the
accumulation of blood in the BP compensator when there was a
rise in BP, the compensator was connected through a Watson-
Mar low pump to a reservoir. The reservoir was connected to
a silicone rubber cannula (3mm id) with side holes, inserted
through the left auricular appendage, so that its tip lay in
the atrium.
The system was primed with a solution containing dextran
(2.57, W/V) and glucose (57, W/V). By transfer of fluid from
the venous to the arterial side of the circulation or vice
versa both MAP and LVEDP could be maintained constant or varied
independently as desired. A water jacket and a heated glass
coil in the reservoir were used to maintain the fluid in the
system near 37°C. All the parts of the system which were made
of glass were siliconed to prevent the formation of pharma¬
cologically active agents when the blood contacted the glass.
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VI Drug administrat ion
Drugs were given after data had been recorded for twenty
minutes to ensure that a steady state level had been achieved.
Noradrenaline bitartrate was given by continuous intravenous
infusion using a Watson-Mar low pump, at a rate within the range
0.05to 0.41 ug/kg/min. The heart was paced at a rate just
exceeding that of the expected spontaneous rate induced by
noradrenaline. The resting levels of all the parameters being
studied were recorded just before the infusion began, the values
of HR, MAP and LVEDP being noted. During the infusion of
noradrenaline, 11R, MAP and LVEDP were held constant at their
preinfusion levels and when a steady state had been achieved the
parameters were again recorded.
Sotalol,prcpranalol and bretylium were injected intravenously
in doubling cumulative doses. The parameters were recorded
before and 5 minutes after the administration of each dose of
drug; HR, MAP and LVEDP being held constant when necessary.
The haemodynamic responses to each of these drugs were observed
following this protocol in normal dogs, in dogs which had been
pretreated with reserpine in order to deplete then of catechola¬
mines and in dogs in which blockade of the effects of circulating
and released catecholamines on the heart was achieved with practalol
10 mg/kg.
0.5 mg/kg of reserpine was given intramuscularly on each
of the two days preceding the experiment, and a third dose was
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given Intravenously at the start of the experiment. This
dosage of reserpine is reported to result in virtually complete
depletion of measurable noradrenaline in the heart within 24
hours (Paasonen and Krayer 1958). Tyramine, 60 ug/kg, was given
intravenously to test for depletion of endogenous catecholamines
in the reserpinized animals. Absence of a change in HR or MAP
to this dose of tyramine is claimed to indicate complete depletion
(Cooper 1961).
Prostaglandin solutions were infused in the cat and dog
into the left ventricular cavity through the indwelling catheter
at a rate of 0.5 or 1.0 ml/min for two minutes. Since prosta¬
glandin C is unstable under alkaline conditions, fresh solutions
were prepared in 0.9% Nacl solution at ph 5.5, from a 3mg/ml stock
solution in methanol, at the start of each experiment. Prosta¬
glandin (PG) C? was prepared from PG A0 using rabbit plasma PGA
isomerase bonded to sephatose 4B gel (Jones 1974). Two kinds of
tests were performed using prostagladins. In one series (controlled
tests) MAP, HR and LVEDP were held constant during the prostaglandin
infusion, so that only direct actions on the heart were seen. In
the other series (uncontrolled tests) MAP and LVEDP were allowed
to change freely under the action of the drug, so that actions on
cardiac performance secondary to changes in arterial pressure and
venous return were seen. After the first infusion of prostaglandin
there was marked tachyphylaxis in the respones to further doses
of prostaglandin. We therefore, adjusted the dose of prostaglandin
to keep the same order of fall in blood pressure in the uncontrolled
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tests. Similar allowance was made for the variation, which was
greater than tenfold, in sensitivity to prostaglandins between
animals.
VII Expression of results.
The results have been expressed, either as the absolute
change or as the percentage change from control valves. Where
the results have been pooled, each bar represents the mean ^
1 standard error of mean (SEM). For each group of experiments
"4"
the control measurements have been expressed as the mean - 1
standard deviation (SD). Regression equations were calculated
by the method of least squares fit. Student's 't * test was used
to evaluate the significance of a change from the control level,
changes being considered significant if P<0.01
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Effect: of heart rate on dP max, SW and cardiac power.
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By adjusting the pacemaker, stepwise increments in heart
rate were brought about. The results of five series of tests
in five dogs are shown in Figures3&4 and the data tabulated in
table A . The mean lowest heart rate was 150 beats/min (SD-22),
the mean MAP was 79 mm Hg (SD- 5), and the mean LVEDP was
2.8 mm Hg (SD- 1.5). During each series of tests, MAP and
LVEDP were held constant within -.3 mm Hg and - 0.3 mm Hg
respectively.
In each animal an increase in HR was accompanied by an
increase in dP max. The calculated regression equation indicates
dt
-1
an increase in cLP max of 66 mm Hg S for an increase in HR of
dt
10 beats/min (Figure 3 ). In two out of five experiments SW
rose to a maximum value, then fell as HR was further increased.
In the other three experiments SW fell as HR was increased.
(Figure 4 )• Mean cardiac power was calculated as the product
of HR and SW. It fell as HR was increased in one experiment
and in tine other four, mean cardiac power rose to a maximum value
then felL as HR was further increased (Figure 4 ).
55
Figure 3. The effect of increasing HR on dP max.
dt
The relationship between the increase in HR and^the change in
dP max. The mean lowest dP max was 1404 mm Hgs (S.D. + 153).
dt dt
Each symbol represents the results obtained in one dog. The





Figure 4. The effect of increasing HR on SW and MCP. Each symbol
represents the results obtained in one dog.
A. The relationship between the increase in HR and the change
in SW. The mean lowest SW was 60.6 mj (S.D. + 18.7).
B. The relationship between the increase in HR and the change
! in mean cardiac power (MCP) MCP (watts) =HR (beats/iwrh) x
SW (mj). The mean lowest MCP was 8.0 watts (S.D.+ 0.6)
faO
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Effect of increased after load on dP max niul SW.
dt
In five dogs MAP was altered by stepwise increments or
decrements of the air pressure in the blood pressure compensator.
The results are shown in Figure 5 , and the data tabulated in
table B .
The mean 11R was 153 beats/min (SD- 9) : the mean LVEDP was
+ 4-
3.2 mm Hg (SD- 1) and the mean lowest MAP was 71 mm Hg (SD- 16),
During each series of observations, HR was held constant and
LVEDP was held constant within - 0.4 mm Hg.
In each animal an increase in MAP was accompanied by an
increase in dP max and in SW. The calculated regression
dt
equations indicate that for a rise in MAP of 10 mm Hg, there is
an increase in djP max of 86 mm Hgs ^ and an increase in SW of
dt
8 mJ.
Effect of increased preload on dP max and SW.
dt "
\
In 6 dogs, LVEDP was increased in a stepwise fashion by
infusion of dextran into the left atrium. The results are
shown in Figure 6 , and tabulated in table C .
The mean HR was 153 beats/min (SD- 5), the mean MAP was
77 mm Hg (SD- 6) and the mean lowest LVEDP was 1.1 mm Hg
(SD- 0.8). During each series of observations, HR was held
+
constant and MAP was held constant within - 5 mm Hg.
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Figure 5. The effect of MAP on (IP max and SW. A- The relationship betweer
ut
increase in MAP and the change in d_P max. The mean lowest djP m.
dt dt
was 1571 mmllgs ^ (SD! 24). The regression equation is Y=8.ol1.8
B The relationship between the increase in MAP and the Change; Lu !
The mean lowest SW was 65.1 mJ (SD+16). The regression equation
is Y = 0.8x1-1.8.
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Figure 6. The effect of LVEDP on dP^ max and SW.
dt
A. The relationship between the increase in LVEDP and the change
in ciP_ max. The mean lowest value for tlP max was 1165 mrnllgs-*-
dt dt
(S.D. + 243). The regression equation is Y = 134x.
B. The relationship between the increase in LVEDP and the change
in SW. The mean lowest value for SW was 22.9 m.I (S.D. !- 10.9)
The regression equation is Y = 10. lx + 2.6,
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In each animal an increase in LVEDP produced an increase
in dP max. This is not a linear relationship, the increases
dt
in d_P max being greater in the lower range of LVEDP. The best
dt
straight line which passes through the observed points and the
origin was calculated to provide an estimate of the effect of a
rise in LVEDP on d_P max. The slope of this line indicates a
-1
rise in dP_ max of 134 mm Hg s for a rise in LVEDP of 1 mm Ilg.
dt
This is probably an underestimate at low LVEDP.
The relationship between LVEDP and SW, however, does seem
to be linear and the slope of the calculated regression line
indicates an increase in SW of 10 mj for an increase in LVEDP
of 1 mm llg.
The relationship between change in dP max and SW during infusion
dt
of noradrenaline.
An example of the records obtained during a single infusion
of noradrenaline is shown in Figure 7 . During this particular
infusion 1IR was held constant at 139 beats/min, MAP at 68 mm Hg ,
and LVEDP at3.2mm Hg. d_P max rose from 1631 to 2617 mm Hg s ^,
dt
SW rose from 54.7 to 83. 6mJ , and SV from 3. 9 to 5.4 mis.
The results of 32 similar tests in sixteen dogs are shown
in Figures 8<S,^ and the data from which these graphs were drawn
is tabulated in table D . The mean HR was 182 beats/min (SD- 22
4-
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Figure 7. Example o£ records obtained after a single infusion
of noradrenaline. Panel A, control. Panel B,
noradrenaline infused at 0.19 ug/kg/min. From above





LOG DOSE OF NA
igure 8. The effect of noradrenaline infusion on dP^ max.
dt
Dose response curve showing the effect of log. rate
of infusion of noradrenaline on the 70 change in cTP max
d-l
The mean resting value for dT max was 1917 mm llgs
dt




Figure 9. The effect of noradrenaline infusion on SW.
Dose response curve showing the effect of log. rate
of infusion of noradrenaline on the % change in SW.
The mean resting value of SW was 56.6 mJ (S.D. + 19.2).
The regression equation is Y = 38.2x - 50.6.
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During each test HR was held constant, MAP and LVFDP were held
constant within — 4 mm Hg and — 0.4 mm Hg respectively.
The regression lines with 95% confidence limits are shown.
Increasing the rate of noradrenaline infusion produced dose dependant
increases in d_P max (P<0.005) and in SW (P<.05). In Figure 10 the
dt
rate of noradrenaline infusion is related to the "L change in approxi¬
mate SW, calculated from the formula SW = SV(MAP-LVEDP), and the 95%
confidence limits have been drawn. Noradrenaline increased approxi¬
mate SW. Although the increases in approximate SW were significant,
the slope of the increase with increasing dose of noradrenaline was
not significant at the 57> level.
In seven out of the thirty two tests, an increase in dP max
dt
was recorded without an increase in either computed or approximate
SW. In all of these cases, although noradrenaline increased the
rate of development of pressure, peak systolic pressure was not
increased (table D).
DISCUSSION
The effect of an increase in heart rate.
From the results shown in Figures it can be seen that as
the 11R rises, dP max continues to increase, although SW and cardiac
dt
power fall above an optimum HR. These effects were associated
with either no change or a slight fall in peak systolic pressure




Figure 10. The effect of noradrenaline infusion on approximate
SW (SWa), i.e. SV (I1AP-LVEDP). Dose response curve
Showing the effect of log. rate of infusion of
noradrenaline on the % change in SWa. The mean resting
value of SUa was 40.2 mj (S.D. +12). The regression
equation is Y =20.2x - 23.
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systole (Figure llTable E ). Thus at high heart rates, a
further increment in HR increases dP_ max whereas peak systolic
dt
pressure is unchanged or decreased slightly. This effect of
an increase in HR on myocardial force of contraction has
previously been reported in isolated mammalian atria (Kruta and
Stejskalova 1960) and in papillary muscle (Sonnenblick 1962:
Blinks and Koch-Weser 1961). In the lie art in situ, when changes
in HR were investigated, ventricular function curves have shown
no change (Mitchell et al 1963) or a decrease in the strength of
contraction (Berglund et al 1958).
It has been postulated that the decrease in tension occurring
in isolated cardiac muscle, at higher frequencies is secondary to
a shortening of the duration of the contraction (Koch-Weser& Blinks 1963:
Sonnenblick 1965). Over a wide range of rate increments the effect
of the increasing degree of activation of the contractile elements
on the amount of tension or pressure developed more than offsets
the affect of the decreasing duration of contraction. At high
heart rates, however, changes in duration become more important
and may determine the direction of a change in the strength of
contract ion.
This effect would explain why at high rates we found that
dP max still increased, although peak systolic pressure, SW and
dt
cardiac power decreased above an optimum HR. Similar observations
by Siegel et al (1964) and Covell et al (1966) led these authors
to conclude that the ventricular function curve was unable to






Figure 11. The effect of increasing heart rate on A, peak systolic
pressure (PSP): and B, the duration of contraction
Each symbol represents the results obtained in one dog.
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were reflected primarily by n change in the velocity of contraction.
Siegel et al (1964) further concluded that changes in contractility
were char.cterised by a change in the velocity dependant aspects
of contraction and therefore the best index of this aspect of
contraction was most reliable as an index of contractility.
However, as previously discussed in the introduction, a
complete description of the contractile state of the heart
requires the use of four variables, namely, the tension in the
contractile component, its velocity of shortening, the muscle
length and the time after excitation. Changes in the velocity
dependant aspects of contraction reflect only one facet of the
contractile state of the heart and indices of this aspect of
contraction, e.g. dP max, can only validly be used to reflect
dt
a change in the force-velocity relationship, i.e. a change in
contractility when force of contraction and velocity of contraction
are changed in parallel.
As seen in Figure 3 and 11, the effect of increasing HR
is an example of a situation where force and velocity are changed
in different directions. In such cases, if only one index,
namely clP max was used to assess a change in the force-velocity-
dt
length relations an incomplete description of the inotropic
intervention would be obtained.
The effect of an increase in afterload.
Our results confirm that an increase in MAP wiLh the heart
rate and LVEDP held constant is accompanied by an increase in SW
and d_P max. It is a fundamental property of muscle that the
dt
work done in a contraction is partly determined by the after load.
If after load is increased, the work done increases from zero,
when the external resistance to shortening is zero, as a function
of afterload up to a maximum value and then decreases to zero,
when the afterload is too great to allow shortening. This
phenomenon! does not by definition include an increase in
contractility, but it has been suggested that, in the whole
heart the response to an increase in aortic pressure also
includes a positive inotropic effect (Von Anrep 1912, Sarnoff
et al 1960b).
Our results support the hypothesis that an increase in
MAP is accompanied by a small increase in contractility, as
indicated by an increase in the value of cTP max of the left
dt
ventricle. dP max, if it occurs within the isovolumic phase of
dt
contraction is not dependant on afterload (Siegel et al 1964).
There has been some dispute in the literature about the exact
point during the isovolumic contraction when dP_ is maximal.
dt
It has been suggested that if dJP max does not occur before
dt
the aortic valve opening, then a change in aortic diastolic
pressure may change d_P max, because the opening of the valve
dt
would then normally limit the magnitude of c^P max.
dt
Examination of our records, however, showed that in all
but three tests, d_P max occurred before the time of aortic
dt
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valve opening, as indicated by the initiation of aortic flow.
In the tests in which dP_ max did not occur before valve opening,
dt
the aortic pressures were the lowest recorded in each of the
series of tests. This suggests that the increase in clP max
dt
which occurred when afterload was raised from a very low level
was partly secondary to the fact that at the lower afterload,
shortening had occurred prior to the achievement of d_P max,
dt
and therefore the value of dj? max was lower than it would have
dt
been otherwise.
The mechanism underlying this positive inotropic effect
is unknown. Starling (1918) attributed this effect mainly
to the improved myocardial perfusion, following the increased
coronary perfusion pressure. The studies of Rosenblueth (1959b).
J
however, have shown an essentially similar response in the right
ventricle, while the coronary arteries were independently perfused.
Local release of catecholamines is unlikely to be involved since
the response has been demonstrated after prqraialol (Clancy et al
1968) and in the reserpinised animal (Blinks and Koch-Weser 1963).
Rosenblueth et al (1959) and Sarnoff et al (1963) suggested that
myocardial contractility is somehow determined by the amount of
work performed by the heart in preceding beats. Sarnoff showed
a net loss of K~*~ during an increase in aortic pressure and
related this to an altered metabolic state which subsequently
influenced the following beats.
A conclusion about the mechanism involved in the increased
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contractility following a rise in MAP, cannot be drawn from our
results. Quantitative assessment of this effect shows that the
changes in d_P max and in SW are proportional to the changes in
cJt
-1
MAP. For a rise in MAP of 10 mm Hg, d_P max rose by 86 mm Hg s
dt
and SW rose by 8 mJ. Although these changes are small compared
to the inotropic changes associated with noradrenaline, they are
large enough to necessitate the control of MAP, if one uses SW
or dP max to measure inotropic changes,
dt
The effect of an increase in preload.
The importance of the influence of initial fibre length or
end diastolic volume on ventricular performance has been appreciated
for many years. Although it has been generally accepted that
stroke work increases as LVEDP is increased, there has been some
disagreement recently as to whether or not dP max is influenced
dt
by changes in LVEDP. Our results confirm the findings of Wallace
et al (1963). Increasing LVEDP, while HR and MAP are held
constant produced increases in d_P max and in SW (Figure 6 )• In
dt
isolated muscle, the rate of force development has been shown to
be linearly related to initial muscle length. Since the rate of




where R is the radius of the ventricle, an increase in end
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diastolic volume, over the range which we studied, must have
had a greater effect on dF_ than on the radius of the ventricle.
dt
Consequently dP max was increased,
dt
For a rise in LVFDP of 1 mm llg, d_P max rose by 134 mm Hg s ^
dt
and SW by 10 mJ. These results are in disagreement with the
findings of Furnival et al ( 1970). They found that d_P max was
dt
independent of preload, and on this basis concluded that d_P^ max
dt
could be used to indicate an inotropic effect even in the presence
of changes in the end-diastolic volume of the ventricle. The
discrepancy between these results may partly be explained by the
difference in the range of end diastolic pressures studied.
Furnival et al observed the effect of a mean increase in LVEDP
of 5 mm Hg from the mean control level of 5 mm Hg. Whereas our
mean increase was 5 mm Hg from a control level of 1 mm Hg.
We observed that the increments in dP max became smaller at
dt
higher end diastolic pressures and as Furnival et al worked over
a higher range of pressures this may explain why they did not
observe consistant increases in dP max.
dt
Our results support the conclusions drawn by most workers
that LVEDP must be maintained constant, when d_P max or SW are
dt
used to assess inotropic changes in the teart.
The inotropic effect of catecholamines
Tn the heart in situ, Wiggers (1927) showed that the effect
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of catecholamines on the contractile state of the heart is
characterised by two distinct alterations in the contractile
process. Catecholamines increase the rate of rise of pressure
in the ventricle and decrease the duration of systole. These
changes indicate that the contractile component must be shortening
faster and that the duration of activity must be reduced. The
increase in dJP max reflects that catecholamines alter the force-
dt
velocity relationship of cardiac muscle. Noradrenaline has
been shown to increase Vmax, the maximum velocity of shortening,
in cat papillary muscle (Sonnenblick 1962) but its action on Po,
the maximum force generating capacity of muscle, has not yet been
determined. Brady (1967) observed that catecholamines did not
alter the contracture tension of frog muscle in high potassium
chloride solution. The failure of catecholamines to alter the
contracture tension suggests that catecholamines do not affect a
mechanism which necessarily governs peak tension development.
He concluded that the consistant effect of catecholamines was to
increase the rate of tension development rather than necessarily
its maximum amplitude. This conclusion was supported by his
finding in rabbit papillary muscle, contracting isometrically,
that if the resting muscle length and the stimulation frequency
are chosen for maximal contraction, then addition of a
catecholamine will only increase the rate of rise and fall of
tension and not the peak tension. Without the presence of
another inotropic intervention, however, catecholamines usually
increase the peak tension. An increase in d_P max would produce
dt
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an increase in Che peak sysColic pressure developed in Che
venCricle, unless Chis effect is offseC by a big decrease in
Che duraCion of conCracCion.
The resulCs of Che presenC sCudy indicaCe ChaC as Che
rate of infusion of noradrenaline is increased, under condiCions
in which IIR, MAP and LVFDP are held constanC aC Cheir preinfusion
levels, there are proportional increases in both clP max and SW.
dt
Furnival et al (1970) working under similarly controlled
conditions did not obtain consistant changes in SW. Three
factors may explain the discrepancy between their results and
ours.
1. They calculated SW by the usual approximation. The true
external SW is the integral with respect to time of the instantaneous
power i.e. the product of pressure and flow and not the product
of the integrals with time of the out of phase peaks of pressure
and flow. This approximation tends to underestimate the changes
induced by catecholamines , since although MAP has been held
constant, systolic pressure is raised. If our values of SW are
compared with those obtained, from the same records, using the
approximation it is found that on infusion of noradrenaline the
changes in computed SW are usually greater than the changes in
approximate SW (table D )• The difference between the two
values of the changes in SW is found to be directly related to
the change in peak systolic pressure, as is shown in Figure 12 .




Figure 12. The relationship between the change in peak systolic
pressure and the discrepancy between the computed change
in SI/ and the conventionally calculated change in SW
(S'./a). The mean resting value of systolic pressure was
118 mm Ilg (S.D. + 16).
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during isoprenaline infusions. This intervention by reducing
the compliance of the arterial tree as well as increasing its
resistance may reduce the phase angle between peak pressure and
peak flow, increasing the SW by a component missed by the
approximation.
3. In the experiments of Furnival et al, for the measurement
of dP max and SW, the hearts were paced at a rate just below
dt
that producing pulsus alternans. The existance of an upper
limit to the contractile response has been noted by a number of
workers (Blinks and Koch-Weser 1963). Under the experimental
conditions of such a high heart rate, the heart is already
working at the upper limit of its contractile strength and the
influence of nonspecific limits on the contractile response
may have interfered with the action of catecholamines.
For this reason, in order to obtain a useful concentration
response curve of an inotropic drug, the heart should be able to
contract under conditions which allow it to respond with changes
in the strength of contraction that are proportional to the
underlying changes in the degree of activation. This is not
the case, if the control strength of contraction is already near





intermediate than at high
of catecholamines may
heart rates has previously
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been shown in isolated muscle preparations. Kruta and
Zadina (1933) showed in isolated guinea pig atria, that as
the frequency of contraction was increased above an optimum
frequency, the effect of adrenaline on the amplitude of contraction
was decreased. In kitten atrial strips, it has also been shown
that catecholamines flatten the interval-strength relationship
at a high level causing the strength of contraction to be
nearly uniform over a range of intermediate and high frequencies.
(Koch-Weser et al 1963 ) . Catecholamines have also been shown
to have no positive inotropic effect, as measured by a change in
developed tension, on the isometric contracture tension of cat
papillary muscle in a calcium rich solution ( Kavaler and Morad
1966). In some experiments, a small decrease in tension was
observed after the addition of adrenaline this effect being
attributed to the decrease in the duration of the contraction
produced by the drug.
From the results shown in Figure 11 , it can be seen that
in the intact heart, which is being stimulated at a rate just below
that producing below pulsus alternans, the duration of contraction
is much reduced and the greatest tension which the muscle is
capable of generating in that time, is probably being developed.
The infusion of a catecholamine under these circumstances may
be unable to increase the peak systolic pressure or to increase
the external work done although d_F max is still increased. In
dt
some experiments we repeated the infusion of noradrenaline at a
rate just below that producing pulsus alternans and in some cases,
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as in Figure 13 , we were able Co illustrate such an effect.
This is another example of a situation in which the force
and velocity of contraction are not changed in parallel.
These effects may explain why in some tests with noradrenaline,
at high heart rates, we observed only an increase in d_P max
dt
without an increase in SW, and also why Furnival et al found
changes in SW to be an unreliable guide to the inotropic effect
of catecholamines.
We have confirmed that dP max is more consistantly affected
dt
by catecholamines than is external work. We have found, however,
that in hearts which are not driven near their limits of performance,
SW is affected in a consistant and dose-dependent manner by
catecholamines. Stroke work calculated without approximations,
under conditions of controlled heart rate, aortic pressure and
filling pressure is a reliable index of inotropic changes and has
the merit of directly assessing the performance of the heart as a
pump. Furthermore under conditions in which d_P max and stroke
dt
work consistantly diverge it becomes misleading to regard changes
in d_P max as inotropic changes,
dt
We have shown that such a situation arises when divergent
changes in the velocity and force of contraction occur, e.g. at
high heart rates and also when the inotropic effects of
catecholamines are observed in the heart which is already working
near the upper limit of its contractile strength. If one attempts
to relate the action of inotropic interventions to the fundamental












DOSE or NOHADHENALINE /icyuin
Dose-response curves for noradrenaline at two heart rates
in one preparation.
Squares represent changes in dP max Circles represents changes
dt
in SW. Diamonds represent changes in PSP. Open symbols represen
changes at 11R 179 beats/min. Closed symbols represent changes a
HR 208 beats/min.
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course of contraction, as well as their effect on peak tension
and rate of development of tension, it would perhaps be more
appropriate to revive the term 'klinotropic effect', as suggested
by Reiter (1972) to denote a change in the rate of development of
tension.
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S E C T r O N 2 •
The haemodynamic effects of pmnranalol ar*d sotalol.
Table 1 shows the basal control levels of the measured
cardiac variables. Heart rate was the only parameter, in
which there was a difference between the control levels in
the dogs given sotalol and those given pro[xanalol. Preliminary
investigations had shown that sotalol but not prcpranalol always
caused a large fall in heart rate. In order that we could observe
the effects of sotalol at constant heart rate, in subsequent
experiments using sotalol, we paced the hearts at the lowest rate
which they could follow.
Effects of sotalol and proixanalol on normal dogs.
After each dose of the drug, HR was held constant at its
control value, MAP and LVEDP were held to within - 5 mm Hg and
-0.5 mm Hg respectively, except in 2 tests when MAP fell 10 mm Hg.
Administration of sotalol, 1-16 mg/kg, caused a decrease in
dP max and in SW (Figure 14 : table F ). The initial dose of
dt
sotalol produced a mean reduction in clP max and in SW of 94.
dt
Subsequent doses produced only minor further changes. A dose of
32 mg/kg usually depressed the heart such that it was no longer
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TABLE I
Control levels of the measured cardiac variables.
V ariable NORMAL DOGS RESERPINIZED DOGS PRACTALOL-
TREATED DOGS
Sotalol Propnualol Sotalol Propranolol Sotalol
n = 4 n = 3 n = 3 n = 4 n = 3
Heart Rate
(beat s/min)




75 - 3.5 77 + 4 80 - 11 79-5 94-5





1444 - 392 1875 - 506 1640 - 508 1490 - 130 2219 - 186
SW (mj) 48.1 ^12.5 49.6 - 9.9 89.4 -24.5 55.4 - 7.3 87.7 - 2.1
Figures quoted are the means of absolute values (- SD) recorded
prior to administration of either sotalol or propranolol in the




Figure 14. The effect of cumulative doses of sotalol on dP max
dt
and SW in 4 dogs, while 11R, MAP and LVEDP were held
constant
A. The rel ationship between the total dose of sotalol and
the change in SW from control + 1SEM. '['he mean resting
value of SW was 48.1 m.J (S.D.+ 12.5)
B. The relationship between the total dose of sotalol and
the change in dp max from control + 1SEM. The mean
dt
resting value of dP^ max was 1444 + 392.
dt
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possible to maintain MAP and LVEDP at their control valves.
There was no difference in the response of SW and d_P max to
dt
sot alo1.
The effects of sotalol on the duration of the ventricular
pressure pulse, the duration of systole and the duration of the
Q-T interval of the ECG are shown in Figure 15 and table F
Dose dependant increases in these three parameters were observed.
At each dose level, the biggest increase in duration was observed
in the ECG.
Propranalol, 0.1 - 3.2 mg/kg, decreased d_P max and SW
dt
(Figure 16 table G ). The reductions in both parameters
following propranalol tfre greater than those observed after
sotalol, the initial mean reduction being of the order of 207,.
Further increases in the dose of propranalol produced no further
reduction until a cumulative dose of 0.8 mg/kg. Doses greater
than 3.2 mg/kg produced a further big depression of the myocardium.
Most animals did not survive a dose of 6.4 mg/kg.
Table G shows the effect ofpropranalol on the duration
parameters. Propranalol, in doses up to 3.2 mg/kg did not produce
any increase in the duration of the Q-T interval of the ECG. In
one out of three experiments the initial dose of propranalol
produced an increase in the duration of the ventricular pressure
pulse. In this particular experiment tlte initial dose of
jropranalol had caused a very large depression of the heart d_P m;ix
dt
decreased by 407, of its control valve. A similar increase in
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Figure 15. The effect of cumulative doses of sotalol on the % change
in the duration of the ECG^, the duration of the
ventricular pressure pulse 13, and the duration of systoleV
The mean control value of the duration of the ECG was 223 ms
(SD +26), of the ventricular pressure pulse was 282 ms
(SD+ 30), and of systole was 235 ms (SD + 18).
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Figure 16. The effect of propranalol on dj^ max and SW in 3 normal dogs,
dt
in which I1R, MAP and LVh'DP were held constant.
A. The relationship between the total dose of propranalol and
the " change from control in dP_ max + 1SKM.
dt
B. The relationship between the total dose of proprananlol and
the change from control in SW + 1SF.'!.
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the duration of contraction was observed, without a corresponding
change in the duration of the ECG , when a dose of 6.4 mg/kg also
produced a large myocardial depression.
Effects of sotalol and propranabl on reserpine pretreated dogs.
All these animals appeared lethargic and depressed 24 hours
after the administration of reserpine . The initial dose of
anaesthetic required was usually reduced to a half of that required
for normal animals. The response to tyramine was measured at
the beginning of each experiment to test the degree of depletion of
catecholamines in the heart. MAP was increased by a mean of 6.8%
and HR by a mean of 1.7%. These responses demonstrate that a
substantial depletion of catecholamines had been produced by the
reserpine. We found the reserpinized preparations to be very
labile and prone to myocardial depression. Subsequently it was
difficult to hold MAP and LVEDP at their control values. After
the administration of each dose of the drug HR was held constant
and LVEDP held to within - 0.4 mm Hg of the control value MAP
was maintainted to within - 5 mm Hg in most tests, although in some
cases a change of 5 - 10 mm Hg was unavoidable.
Figure 17 and table H shows the pooled data from three
reserpinized dogs after administration of sotalol, 1-32 mg/kg.
In one experiment, sotalol caused a 40 - 507.. depression of
contractility over the whole dose range. This effect was
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Figure 17. The effect of sotalol on 3 reserpinized dogs. While HR,
IIAP and LVEDP were held constant.
A. The relationship between the total dose of sotalol and
the change in SW from control + ISEM.
B. The relationship between the total dose of sotalol and
the "L change from control in d_P max + 1SEM.
dt
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inconsistant with the results from the other two experiments.
Inclusion of this experiment into the pooled data, however,
would make our results indicate that sotalol has apparently a
greater negative inotropic effect in reserpinized than in normal
dogs.
The effects of sotalol on the duration parameters are
shown in Table H . In the inconsistant experiment sotalol did
not cause any change in the duration of the Q-T interval of the
ECG. The increase in the duration of the ventricular pressure
pulse observed in this experiment was associated with a large fall
in the contractile state of the heart. In the other reserpinized
dog, which received the full dose range, we observed a consistant
increase in the duration of ECG and of the ventricular pressure
pulse.
The effect of increasing doses ofpropranalol on d_P max and
dt
SW in 4 reserpinized dogs is shown in Figure 18 and table I
There was no reduction in djP max and SW until a cumulative dose
dt
of 1.6 mg/kg had been given. Further doses ofpropranalol depressed
the heart. A cumulative dose of 6.4 mg/kg was usually fatal.
In each of the four reserpinized dogs, propranaloldid not
increase any of the duration parameters (table I ).The maximum
change observed in these measurements was a decrease of 13 ms



















The effect of propranalol on 4 reserpinized dogs, in which
HR, MAP and LVEDP were held constant.
The relationship between the total does of propranalol and
the 7 change from control in SW + 1SEM.
The relationship between the total dose of propranalol and
the "A change from control in d_P max + IS KM.
dt
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The effect: of sotalol after prnctnlol
We decided Co repeat the experiments using sotalol, after
B adrenergic blockade of the heart had been achieved with
practalol, 10 mg/kg, because the reserpinized experiments had
been difficult to control satisfactorily and also because we
wanted to exclude depression to B blockade of circulating
catecholamines observed in both normal and reserpinized dogs.
We found this preparation to be very stable and MAP could easily
be controlled.
Doses of sotalol below 4 mg/kg had no effect on dP max
dt
and SW recorded after the administration of practalol. Further
doses produced a small negative inotropic effect, the maximum
decrease being 10% at a dose level of 16 mg/kg (Figure 19 table J ).
Figure 20 and table J shows the effect of sotalol on the
duration parameters in these three animals. The increases in all
three parameters were dose-dependent. The most noticeable difference
between these results and those obtained in normal dogs is that the
increases in all three parameters, at each dose level, are reduced.
















Figure 19. The effect of cumulative doses of sotalol in 3 dogs,
which had received practalol. HR, MAP and LVEDP were
held constant.
A. The relationship between the total dose of sotalol and
the 7o change from control in SW + iSEM.
B. The relationship between the total dose of sotalol and
the % change from control in dP max + 1SEM
dt
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Figure 20. The effect of cumulative doses of sotalol, in dogs which had
received practalol, onthe "L change in the duration parameters
The mean control duration of the ECG,A, was 231 ms(SD+ 16),
of the ventricular pressure pulse ,H , was 2 72 ms (SD+ 5), and
of systole,^ , was 213 ms (SD_t 7).
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DISCUSS TON:
SotaloL and propranaloL are members of a series of drugs
which are specific competitive antagonists against the action
of sympathomimetic amines on the B receptors in the heart.
Evidence from experiments on the myocardial depression exhibited
by these drugs has led to conflicting conclusions about the
relative effects which result from B blockade and also a
non-specific direct depressant action not related to the adrenergic
blocking properties of these compounds. Nayler (1970) states
that the negative inotropic effect of propnrtalol at a B blocking
concentration of 0.2 mg/kg, cannot be explained by B blockade alone.
Harry et al (1973), however, state that in doses below 1 mg/kg
propranalol is devoid of a directly depressant action on the heart.
Sotalol on the other hand, has been reported to have no direct
negative inotropic effect, at B blocking doses (Lish et al 1965).
Furthermore, Kaumann and Blinks (1967) and Parmley et al (1972)
reported that sotalol had a positive inotropic action on isolated
muscle preparations, which was not due to B adrenoreceptor
s timulation.
Many studies of the comparative inotropic actions of B blocking
agents on intact hearts are difficult to interpret because effects
on the heart due to drug induced changes in HR, MAP and LVEDP have
not been eliminated. This preparation enabled us to investigate
the direct actions of sotalol and propranalol on d_P max and SW
dt
without secondary effects due to changes in heart rate, MAP and LVEDP.
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Sotalol, 1-16 mg/kg, decreased both d_P max and SW by a mean of
dt
97, in normal dogs. This depression occured after the initial
dose; subsequent doses within this range, did not further depress
the myocardial force. This suggests that the initial fall in
dP max and in SW was due to blockade of the positive inotropic
dt
action of circulating catecholamines. This suggestion is supported
by the absence of this initial fall in dP max and in SW in dogs
dt
in which the action of circulating catecholamines on the heart had
previously been blocked by practalol. In two out of three
catecholamine depleted dogs, sotalol did not produce a direct
depression of the myocardium. The result from the third reserpin-
ized animal is inconsistent with the findings of the other
experiments, as the initial dose of sotalol caused a large fall
in d_P max and in SW. This effect was probably related to the
dt
general instability of the reserpinized preparation rather than
a negative inotropic action of sotalol. We conclude, therefore,
that in doses below 16 mg/kg, sotalol does not have a direct
negative inotropic action on the myocardium. Doses of sotalol
above 16 mg/kg did depress the heart in all the animals studied,
by a direct negative inotropic action.
Propranalol, 0.1 - 1.6 mg/kg, depressed d_P max and SW by
dt
20 - 257. in normal dogs. Since these reductions were not observed
in catecholamine depleted animals, these changes must have been
due to antagonism of the effects of catecholamines at the cardiac
B receptor sites. Propranalol, in doses below 1.6 mg/kg, does
not have a direct negative inotropic effect, although at higher
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dose levels, it has a marked depressant action.
Previous animal experiments have shown that the ratio of
the activities of sotalol andpropranalol as B adrenergic blockers
is within the range of \ (Farmer and Levy 1968) to /17 (Raper
and Wale 1968). Using a dose ratio of 16:1 (sotalo1:Propranalol),
the responses in normal dogs of equiactive B blocking doses of
propranalolC0.5 mg/kg) and sotalol (8 mg/kg) can be compared from
Figurel4 and 16 . It can be seen that at equiactive blocking
doses .propranalol caused a greater decrease in both dP max and in
dt
SW than sotalol.
The other characteristic difference between the actions of
sotalol and propranalolwhich we observed was that sotalol caused
a greater depression of free heart rate than propranalol. We
have no quantitative estimate of this effect as we were primarily
interested in observing the actions of sotalol at constant heart
rate. In five preliminary experiments, however, we observed that
a dose of 2 mg/kg of sotalol reduced the heart rate from a mean
of 164 to 134 beats/min, whereaspropranalol caused no significant
change in heart rate.
A general lack of parallel changes in inotropic and chrono¬
tropic properties following sotalol andpropranalol has previously
been suggested (Puri. and Bing 1969, Gomoll and Braunwald 1973).
Gomoll and Braunwald (1973) reported findings similar to ours
i.e. that at equiactive B blocking doses,propranalo1 promoted a
greater decrease in both contractile force and in dP_ , while
dt
97
sotalol produced the more profound slowing of heart rate.
Their experiments were undertaken in a dog aortic bypass
preparation which was denervated and in which aortic flow
and pressure could be controlled. They found that in the
non-reserpinized bypass preparation, a 22% (46 beats/min)
slowing of HR following propranolol(1 mg/kg) was accompanied
by a 267, (490 mm Hg s ^) decrease in djP max. Sotalol (8 mg/kg)
dt
however, produced a 44% (94 beats/min) reduction in HR which was
associated with an 18% (300 mm Hg s ^") depression in d_P max.
dt
In the reserpine pretreated dog given propranolol,a 2% (3 beats/
min) slowing in HR occured with a 14% (230 mm Hg s ^) decrease
in dP max, whereas after sotalol a statistically significant
dt
(P<,01) 19% (27 beats/min) lowering of HR was accompanied by a
6% (130 mm Hg s ^) reduction in d[P max.
dt
Singh and Vaughan Williams (1970) postulated that sotalol's
ability to prolong the duration of the action potential and the
duration of the contraction might be responsible for its less
depressant action on the myocardium.
The results of our experiments support the findings of Strauss
et al (1970) and Singh and Vaughan Williams (1970), who showed in
dog and cat isolated ventricular fibres, stimulated at a constant
cycle length, that sotalol prolonged the duration of the action
potential by slowing repolarisation. In our experiments, sotalol
increased the duration of the Q-T interval of the HCG in a dose
dependant manner in normal dogs (Figure 15 ). This action of
sotalol was also observed in dogs, pretreated with practalol,
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although the magnitude of the effect was reduced ( Figure 20 ).
Of the two catecholamine depleted dogs, given the complete dose
range of sotalol, one showed an increase in the duration of the
Q-T interval of the ECG following sotalol. Propranolol, however,
did not increase the duration of the Q-T interval of the ECG
in any of the experiments, but decreased it in one experiment.
The results confirm the findings of Morales-Aguilera and
Vaughan Williams (1965 ) in isolated rabbit atria, which showed
that propnnalol slightly reduced the duration of the action
potential.
The action of sotalol on the duration of the action
potential may result from a direct effect of the drug on the
electrical properties of the myocardium or from its antaganism
of the electrical effects of circulating catecholamines. The
fact thatpronranalol,in doses which block the inotropic effects
of circulating catecholamines, does not prolong the duration of
the ECG, is not itself evidence that the action of sotalol must
be more than a blocking action of the electrical effects of
catecholamines. We cannot conclude from our results if this
action of sotalol persists in catecholamine-depleted dogs. We
would have liked to continue the experiments in reserpinized
preparations but the relatively high failure rate in these animals
and the limitation in the number of dogs which were available
to us led us to stop these experiments when it became obvious
that a large number of dogs would be needed to obtain a
conclusive result. The effect of sotalol after B adrenergic
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blockade in the heart had been produced by practalol, however,
indicates that although a part of the action of sotalol in normal
dogs is due to the antagonism of the electrical effects of
catecholamines (the change in the ECG induced by sotalol was
smaller after practalol) a direct prolongation of the action
potential is also likely. This evidence is not conclusive
since practalol itself has been shown to have B stimulant actions
(Barrett and Carter 1970).
The changes in the duration of the ECG, after sotalol, were
associated with increases in the duration of contraction, as
indicated by changes in the duration of the ventricular pressure
pulse, and also with increases inthe duration of systole. The
larger increases in the duration of contraction than in systole,
at each dose level, indicates that the relaxatiori process, after
aortic valve closure, was particularly prolonged. If this
prolongation of the contraction were contributing to the lesser
negative inotropic effect of sotalol than propranalol, one would
have expected to observe a differential effect on SW and d_P max.
dt
From the mechanical properties of muscle, one would expect that
an increase in the duration of the contraction would increase the
tension or shortening developed and hence the work done in a
contraction without necessarily increasing the rate of development
of tension. Our results, however, always showed consistent changes
in d_P max and in SW. We found no evidence to support a positive
dt
inotropic action of sotalol, as indicated by an increase in SW, on
the intact heart. In dogs, given practalol, sotalol produced no
LOO
change Ln d_P max and in SW until doses greater than 16 mg/kg,
dt
which iiad a negative inotropic action. This implies that although
the duration of contraction was increased by sotalol, the effect
was either not large enough or not early enough to be reflected
by a change in SW.
The failure of sotalol to produce an increase in SW or clP max
dt
in dogs given practalol, makes it very unlikely that a direct
positive inotropic action of sotalol, mediated by an increase in
the duration of contraction, is responsible for the less depress¬
ant effect of sotalol thatpropranalo1, as suggested by Singh and
Vaughan Williams. It has been postulated that the reason for
the differences in haemodynamic response between sotalol and
propranolol may be the presence of the depressant properties of
propranolol. However, our results on reserpinized dogs have
shown that in doses below 1.0 mg/kg propranolol does not possess
a direct negative inotropic effect. These results have recently
been confirmed by Harry et al (1973). They were investigating
the B blocking and inotropic effects ofpropranalo1 on the intact
dog heart, and found that a dose of 0.05 mg/kg of propranalol
decreased control lieart rate by 1% although the change in control
d? max was - 257.. They also showed that propranalol had a
dt
differential blocking effect on the two responses, heart rate and
contractility, induced by isoprena1ine. For a given change in
free heart rate, induced bv isoprenaline, dP_ max was less in the
dt
presence ofpropranalol. In order to explain their results, these
authors concluded that in the denervatcd heart, because the uptake
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process for sympathomimetic amines in the myocardium is smaller
than that which occurs at the sinu-atrial node (Furnival et al
1971), the concentration of circulating catecholamines in their
preparation was not high enough to affect heart rate, but was
high enough to have an effect on dP_ max equivalent to about 257,
dt
and it is this effect which is blocked by propranolol. Therefore,
propranalolis able to block the effect of endogenous circulating
catecholamines only in the myocardial muscle and subsequently there
is a fall in d_P max with no change in heart rate,
dt
Although this reasoning can explain the experimental results
observed with propranalo1, it fails to explain the comparative
effects of sotalol and propranalol. We have shown that at
equiactive B-blocking doses,propranalo1 promoted greater decreases
in contractility, while sotalol produced the greater slowing of
heart rate. Moreover Brooks et al (1971) have shown in the intact
dog heart that sotalol blocked the isoprenaline induced chronotropic
response by 427, although the inotropic response was only slightly
decreased. This effect is the opposite to that observed with
propranolol (Harry et al 1973). These comparative effects of
sotalol and propranalolcannot be explained on the basis of differ¬
ential uptake of sympathomimetic amines into the sinu-atrial node
and myocardial muscle.
The marked effect of sotalol on free heart rate and on heart
rate changes induced by isoprenaline may be due partly to a direct
effect of sotalol on the declrical properties of the myocardium.
As stated previously, we have been unable to conclude from
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our experiments whether such an effect exists. The difference
in the inotropic responses to sotalol and propranalol cannot be
explained by a superimposed positive inotropic effect of sotalol
nor by an additional negative inotropic effect of propranalol.
The differential responsiveness of heart rate and contractility
to B adrenergic blockade raises the possibility of qualitative
differences in the receptor sites mediating beta adrenergic
responses. Sotalol may be less efficient in blocking B receptors
in the myocardium than propranalol: whereas proprananlol is less
efficient in blocking the B receptors in the sinu-atrial node.
From these experiments, however, we can only infer that the
differential chronotropic and inotropic responses to sotalol and
propranalol, indicates different sub groups of cardiac B receptors.
Clinically there may be potentially significant benefits to
be gained from the use of a B blocking compound, like sotalol.
Its greater chronotropic blocking action may make it particularly
useful as an anti-anginal agent, since heart rate is a major
determinant of myocardial oxygen consumption. However, sotalol
has less of a negative inotropic action than propranalol, and
this would seem to be a particularly important property when it
is desired to achieve B blockade in patients with impaired myocardial
function. Sotalol's greater chronotropic B adrenorecept:or blocking
properties may make it a safer antiarrhythmic for patients with
myocardial infarction, in whom a negative inotropic effect would be
dangerous .
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S K C T T O N 3
R I- S II I T S
Haemodvnamic actions of hretvlium tosvlate
The effect of bretvlium
1. on the normal dog.
When bretylium was administered to a normal dog, a dose of
0.4 mg/kg, produced a 55% increase in d_P max and a 77% increase
dt
in SW, measured at constant IIR, MAP and LVEDP. With doses
greater than 1.6 mg/kg, however, it was no longer possible to
maintain the 11R at its control value. After a single injection
of 10 mg/kg we made no attempt to control the pressures and HR.
HR rose from 150 to 208 beats/min MAP initially fell. The fall
in MAP, which lasted less than 1 minute, was associated with
either an increase or no chai ge in cardiac output and was therefore
assumed to be due to peripheral dilatation. It was followed by
a rise in MAP from the resting level of 85 rrmHg to 140 mm Hg.
These changes were accompanied by a very large increase in d_P max
dt
and SW.
2. On catecholamine depleted dogs.
All these animals appeared lethargic and depressed 24 hours
after the administration of reserpine. The initial dose of
anaesthetic required was usually reduced to a half of that required
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for normal animals. The response to tyramine was measured at
the beginning of the experiment to test the degree of depletion
of catecholamines in the heart, MAP was increased by a mean of
12% (range 2-29%) and HR was increased by a mean of 1% (range 0-3%).
These responses demonstrated that substantial depletion of catechola¬
mines had been produced by the reserpine.
Figure 21 , shows the pooled data from 5 reserpinized dogs.
The data from which these results were obtained are tabulated
in table k •
The mean HR was 136 beats/min (SD- 19), the mean MAP was
76 mm Hg (SD- 12), and the mean LVEDP was 1.7 mm Hg (SD- 0.7).
For each test, HR was held constant, MAP was held to within - 4mm Hg
of the control valve, except in 3 tests, and LVEDP was held to
within - 0.4 mm Hg of the control value.
Compared with the responses in the unreserpinized animals
the inotropic responses are markedly attenuated and increases in
the dose of bretylium above the initial dose do not produce
further increases in the inotropic responses. The increases in
dP max and in SW produced by bretylium in the reserpinized
dt
animals were significant.
Although the pressor responses were also markedly attenuated
in the reserpinized animals, the initial vasodilatation was
comparable in magnitude in the reserpinized and in the normal dog.
The effect of bretvlium on the duration of the ventricular
LOS
Figure 21. The effect of bretylium on dP max and SW in reserpinized
dogs.
A. The relationship between the log total dose of bretylium
and the °L change in SW from control + 1SEM. The mean
resting value of SW was 62.4 mJ (SD + 8.9).
B. The relationship between the log total dose of bretylium
and the % change in d_P max from control + 1SEM. The mean
dt
-1
resting value of dj? max was 1340 mm Hgs (SD + 327).
dt
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pressure pulse, the duration of systole and the duration
of the ECG are shown in table 2. There was no consistent
effect of bretylium on the duration of the ECG, but the positive
inotropic effects of bretylium were accompanied in each of the
five experiments by a shortening in the duration of systole
and of the ventricular pressure pulse. The maximum shortening
was of the order of 5 to 11% of the control values.
3. On dogs after blockade of the receptors in heart.
Bretylium in doses up to 16 mg/kg, when given after practolol,
produced no change in cLP max and SW measured at constant HR, MAP
dt
and LVEDP in 3 dogs. Doses greater than 16 mg/kg reduced dP_ max
dt
and SW (Figure 22). The data from which these results were
obtained is tabulated in table L. The mean 1IR was 161 beats/min
(SD+9), the mean MAP was 85 mm Hg (SD+2), and the mean LVEDP was
2.6 mm Hg (SD+ .09). For each test, MAP and LVEDP were held to
within + 5 mm Hg and + 0.5 mm Hg of the control values respectively.
The initial fall in MAP was unchanged from that in the normal
animal, but the delayed rise in MAP was smaller than the increase
observed before blockade. As the dose of bretylium was increased,
the initial fall in MAP became larger and longer in duration. At
doses greater than 16 mg/kg, MAP did not fully recover from the
initial fall and the delayed increase in P did not occur (Figure 23).
The effects of bretylium, after practolol, on the duration of
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TABLE 2.


















CONTROL 258 224 246
1 243 206 246
2 256 221 240
4 255 217 241
8 253 216 244
16 258 223 245
32 246 205 234
Figures quoted are the means of five experiments. Full









Figure 22. The effect of bretylium on dP max and SW after practolol
dt
A. Ihe relationship between log total dose of bretylium and
7° change in dTF nax. The mean control value of dP max
dt
_i dt*
was 1644 mm Hgs (SD + 434).
B. The relationship between log total dose of bretylium
and % change in SW. The mean control value of SW was
44.6 mJ (SDI- 28.9).
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Figure 23. The effect of bretylium on MAP.
A. brctylium, 8 mg/kg
B. brctylium, 16 nig/kg
The records from above downwards arc:- C.O. , LVEDP,





the ventricular pressure pulse of systole and of the ECG are
shown in table 3. In one experiment out of three, bretylium
in doses above 4 mg/kg caused a small increase in the duration of
the ECG, and of the ventricular pressure pulse although the duration
of systole was unchanged. The maximum increase in duration was of
the order of 57, above control values. In the other two experiments
there was no change in any of the three duration measurements.
Discussion.
The marked positive inotropic and chronotropic effect of
bretylium in the normal dog is associated with its ability to
release noradrenaline from adrenergic nerve endings before
producing adrenergic blockade (Boura and Green 1959). In
order to investigate the direct action of bretylium on the relaxation
process in the myocardium, it was therefore necessary to deplete
the animals of endogenous catecholamines by prior administration
of reserpine. The results of our experiments in reserpinized
animals demonstrate that within the range of doses employed, 0.1
to 64 mg/kg, bretylium does not prolong relaxation unless the
prolongation is masked by the effect of released catecholamine.
Markis and Koch-Weser (1971) were able to show, in reserpinized
kitten papillary muscle, a prolongation of relaxation with a
concentration of bretylium of 3. 10 '"Hi. In normal myocardium
they also showed that bretylium did not alter the time required
I11
TABLE 3.


















CONTROL 263 205 181
1 264 204 182
2 264 204 183
4 263 206 184
8 268 210 186
16 2 75 214 191
Figures quoted are the means of three experiments. Full
data are tabulated in table L.
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for 90% relaxation. As they concluded that bretyHum's
positive inotropic action was due to the release of catechola¬
mines, which shorten relaxation time (Koch Weser and Blinks 1963),
they also proposed tluit bretylium had a direct action to slow
myocardial relaxation.
This conclusion obtained from isolated muscle studies is
not supported by our results. The positive inotropic action
of bretylium although much attenuated in reserpinized muscle was
not abolished. It was associated with an increase in the rate of
development of pressure and a moderate but consistant decrease in
the duration of systole. These results suggest that the degree
of activation of heart muscle is increased and that the maximum
intensity of contraction is achieved sooner in the presence of
bretylium. The changes in the time course of contraction seen
after administration of bretylium are identical to those produced
by noradrenaline. In view of the known catecholamine releasing
properties of bretylium, we decided to observe the action of
bretylium after the receptors in the heart had been blocked
by practolol. The results of these experiments clearly
demonstrate that the positive inotropic effect of bretylium is
completely abolished after beta blockade. We conclude,
therefore, that the observed positive inotropic effect of
bretylium is entirely indirect and is due to the release of
catecholamines from their storage sites in the nerve endings in
the myocardium. This conclusion supports the earlier findings
of Gilmore and Siegel 1962 who demonstrated an increase in coronary
LL3
venous catecholamine levels after bretyllum administration.
We have found no evidence for a direct positive inotropic
action of bretylium. In the one experiment in which we did
observe a prolongation of the ventricular pressure pulse, there
was no change in the duration of systole. This implies that the
observed increase in duration was due to a slowing of the tail
of the ventricular pressure curve. Such an effect could not
explain the discordant results of Amsterdam et al (1970) and
Gaffney and co-workers (1961 and 1962). The results of
Amsterdam et al are difficult to explain as the dose of propranalo
-4
(10 M) which they used ought to have been sufficient to produce
complete B blockade. The findings of Gaffney and co-workers
could be explained if incomplete depletion of myocardial stores
of catecholamines by reserpine pretreatment and by cardiac
denervation had occurred.
This conclusion implies that the standard regime for
reserpinization and the standard test for complete depletion
of endogenous catecholamines in the heart are not adequate.
We tested the effects of larger doses of tyramine in a dog which
had been depleted of catecholamines using the normal dose regime
of reserpine. The response to 60 ug/kg of tyramine was measured
at the beginning of the experiment as usual. MAP increased by
4% and there was no change in I1R. These changes fall within the
range of changes observed during the same test in the dogs used
to investigate the action of bretylium. Figure 24 shows the
effect of higher doses of tyramine in this animal. A dose of
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Figure 24. The inotropic and chronotropic effects of high doses
of tyramine in one reserpinized dog.
The relationship between the log dose of tyramine and
the 7o change from control in dJP max, S3 , SW, • , and
dt
free 11R.V . For the measurement of d_P max and SW, HR,
dt
MAP and LVEDP were held constant, during each test, at
the respective values of 121 beats/min 85 mmllg, 2.0 mm Hg.
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3.5 mg of tyramine produced a 20% increase in d_P max and in SW.
dt
Further increases in the dose of tyramine did not produce further
increases in the inotropic responses. The positive inotropic
effect of tyramine was accompanied in each test by a decrease in
the duration of systole and of the ventricular pressure pulse.
These doses of tyramine produced a similar response to bretylium
in reserpinized hearts. The responses observed were also
equal in magnitude. This implies that tyramine and bretylium were
acting on the same pool in the nerve endings to release a small
fraction of catecholamines which had remained resistant to the
depleting action of reserpine. Both intraneuronal (Crout et al
1962) and extra neuronal (Fischer et al 1965) reserpine resistant
pools of noradrenaline have been postulated in adrenergic nerve
endings, from which tyramine is capable of releasing noradrenaline.
Experiments have shown that exposure of reserpine treated tissue
to catecholamines can result in the 'refilling' of the pools.
Crout et al (1962) for example, found that the response of the
reserpinized guinea pig atria to tyramine could be restored to 70%
of normal values although the amount of noradrenaline accumulating
in the tissue was only 2.2% of the normal level. In reserpinized
rat atria, it has also been shown that if doses of bretylium and
tyramine, which previously caused no significant inotropic effect,
were given after exposure of the atria to noradrenaline, then they
both produced a positive inotropic action of the same magnitude
which was observed in our experiments (Bhagat and Shideman 1963).
The release of catecholamines from the adrenal medulla during
induction of anaesthesia or as a result of surgical shock during
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our experiments may have resulted in sufficient re-uptake of
catecholamines}into the nerve endings, to partially restore
the response to tyramine and bretylium. The results of these
experiments, therefore, suggest that the lack of an IIR change
to 60 ug/kg of tyramine is not sufficient to enable one to make
the assumption that adequate depletion of catecholamine stores
in the myocardium has been achieved. This is especially
important when one is investigating the actions of drugs which
are powerful releasers of catecholamines.
Bretylium produced an initial peripheral dilatation in all
the dogs studied. The magnitude of this depressor response
was unaffected by reserpinization. It is probably due to the
relatively weaker cholinergic effects of bretylium as previously
suggested by Yelnosky and Mortimer (1961). With the higher
doses of bretylium the initial depressor response became larger
and longer in duration. At doses greater than 8 mg/kg the MAP
did not fully recover from this initial depression. This
observation may have an important bearing on the clinical use




The cardiovascular actions of prostaglandin C ami II in the cat and doe.
INTRODUCTION
Although studies have been made on the actions of the
different prostaglandins on the cardiovascular system, these have
been mostly limited to investigating their effects on the arteries
and veins(Nakano 1973). The inotropic actions of prostaglandins
are difficult to evaluate partly because of their potent actions
on the peripheral vascular system and also because a considerable
species variation in their vascular and cardiac actions limits
the extrapolation of experimental data.
Prostaglandin (PG) C has recently been shown to be produced
from PGA by an isoraerase enzyme present in the plasma of a
number of species including the cat and dog (Jones 1972a).
The purified prostaglandins C^ and C9 were tested for bio-activity
in the cat and were found to be several times more potent as a
vasodilator than the precursor PGA (Jones 1972b). These experiments
also showed that the vasodilator effect of PGC was much more
prolonged than that observed with PGE. The prostaglandins C pass
through the pulmonary circulation of the cat with negligible loss
of vasodepressor activity (Jones and Cammock 1973) unlike the
prostaglandins E which are extensively metabolised by the lungs
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(Ferreira and Vane 1967). Thus lC was thought that this prolonged
effect of PC.C was simply a reflection of the longer half-life of
PGC in the circulation.
Preliminary investigations, however, revealed that following
an intravenous infusion of PGC9 into the cat, a biphasic change
in aortic flow occurred, a transient rise followed by a fall,
the latter coinciding with the prolonged depression of arterial
blood pressure. An example of this effect is shown in Figure 25 .
We have investigated the secondary fall in aortic flow and its
relationship to the prolonged depressor effect to elucidate
whether prostaglanins C have actions on the cardiovascular system
other than dilatation of the arterioles. We considered three
possible actions of PGC.
1. a negative inotropic action on the heart.
2. Contractility depressed by the fall in arterial pressure.
3. A reduction in venous return.
Prostaglandins E have been reported to increase myocardial
contractile force in the dog, but not under conditions of constant
HR, MAP and LVEDP (Nakano and McCurdy 1967, 1968, Nakano and Cole
1969). We therefore extended our study to the dog and included
prostaglandin Efor comparison.
The preparation was established as described in the methods
sect ion.
RESULTS: The effects of prostaglandins C^ and C0, E^ and E^ were
investigated in the cat.
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Figure 25. Shows the values of arterial blood pressure and
aortic blood flow at 10s intervals of time, after
a single intra-aortic injection of 3.5 ug PGG, into
a 4.5 kg cat.
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Uncontrolled tests in the cat.
Figure26 and tableM shows the results obtained when LVEDP
and MAP were allowed to change freely during an infusion of PGC.
In all tests MAP, <iP max and SW fell. In 11 out of 13
dt
tests LVEDP also fell. It was not possible to do a parametric
analysis of the individual tests because -
a) the resting levels of the parameters varied between experi¬
ments .
b) the animals varied in sensitivities to the prostaglandins and
c) in a number of instances long lasting tachyphylaxis to the
prostaglandins made it difficult to show dose dependant
responses.
i 2
However, on a non-parametric basis as judged by the X test the
change in LVEDP is significant (P<j0.01).
Controlled tests in the cat.
The results of the controlled tests for various infusion
rates of PGC and PGE are shown in table N } and figure 27 .
During each infusion HR was held constant, MAP and LVEDP were
+ +
held to within - 4 mm Hg and - 0.3 mm Hg respectively of their
control valu es.
There were no consistent changes in dj? max or SW. It can
dt
thus be concluded that neither PGC nor PGE has a direct inotropic














Figure 26. The effect of PGC (0.06 - 5.6 ug/kg/min) on the %
change in LVEDP, MAP, dj? max and SW, in the cat,
dt
when no constraints were applied. The graph shows
the means + 1SEM for 13 tests in 5 cats. The mean
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Figure 27. The effects of PGC arid PGE on the "L change in dP max
dt
and SW in the cat, when LVEDP, MAP and HR were maintained
at their resting levels. The graphs show the means
+ 1SEM of six tests for each prostaglandin in three cats.
The infusion rates varied between 0.06 and 5.6 ug/kg/min
for PGC and 0.3 and 2.8 ug/kg/min for PGE. The mean
control levels of each parameter are shown in table N.
123
Controlled tests Ln the doi;.
The effects of PGC„ and were investigated in the dog.
Heart rate was held constant, MAP and LVEDP were held constant
~f~ "4~
to within - 3 mm llg and - 0.3 mm Hg respectively. An increase
in dP max and SW occurred in each test, indicating a positive
dt
inotropic action on the myocardium. The results are shown in
table 0 and figure 28 . The changes in MAP and LVEDP were not
significant whereas cM max and SW increased significantly (PCO.Ol)
dt
with both prostaglandins and .
Uncontrolled tests in the dog.
In some tests we observed the action of PGC„ and E„ when2 2
constraints on MAP and LVEDP were not applied(Figure 29 and
table P ).With both prostaglandins, MAP fell, SW was unchanged
although dlP max was significantly increased (P<0.01).
dt
DISCUSSION
We have shown that doses of PC.C which lower the arterial
blood pressure of the cat also lowers its LVEDP, d_P max and SW.
dt
The effect on dP_ max and SW is not seen in the paced heart if
dt
both LVEDP and MAP are held constant. This is also true with
PGE. We conclude therefore, that these prostaglandins have
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Figure 28. The effects of PGC^ and PG29 (0.07-1 ug/kg/min) on
the 7<phang"s in dP^ max and SW of the dog heart, when
dt
LVEDP, MAP and HR were maintained at their resting
levels. The figure shows the means + 1SEM of 4 tests
with PGC2 and 6 tests with PGE2 in three dogs. The mean






















Figure 29, The effects of PGC9 and PGE9 (0.07 - 1 ug/kg/min) on the




The figure shows the means + 1SEM of 2
Theand 5 tests with PGE2 in two dogs,
mean control values of each parameter are shown in table P.
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for the fnlL in aortic flow seen in our preliminary experiments
with PGC must, therefore, lie in an action on the peripheral
circulation. The fall in dP_ max and SW, in the uncontrolled
dt
state^an be accounted for partly by the fall in arterial pressure
and partly by the fall in LVEDP. The fall in arterial pressure
is associated with tlie known potent vasodilator properties of
PGC (Jones 1972b). The fall in LVEDP in conjunction with a fall
in cardiac output indicates a reduced venous return. • The
mechanism of this reduction in venous return is not known.
Von Euler (1939) found that a crude PG extract increased
portal venous pressure and caused blanching of the liver.
Pooling of blood in the portal circulation, due to constriction
of vessels in the liver would reduce venous return. Another
>
possibility is that PGC may dilate capacitance vessels. This
could be a direct action on smooth muscle, or an inhibition of
adrenergic venomotor tone. Death from circulatory collapse
which is seen with large doses of PGC in the cat can be explained
by the combination of vasodi lat at ion and reduced venous return.
In contrast with their actions in the cat, PGC2 and PGE^
exert positive inotropic actions in the dog. The two compounds
are of the same order of potency. These results confirm the
findings of Nakano and McCurdy (1967) who showed that PGE^ increased
myocardial contractile force in dogs. Since our measurements
were made at constant I1R, MVP and LVEDP, the changes in d_P max and
dt
SW seen in Figure 28 indicate the extent of the direct inotropic
action in the absence of effects secondary to peripheral vascular
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actions of the prostaglandins.
The mechanism by which PGE and PGC exert their inotropic
effect in the dog is not known. The cardiac effects of these
prostaglandins cannot be mediated by reflex sympathetic stimulation
of the heart as a consequence of the decreased systemic arterial
pressure, since in these experiments the heart was denervated.
Nakano and McCurdy (1967) also showed that the inotropic effect
of PGE was present in dogs pretreated with lmg/kg of propranolol
a dose which completely blocks the cardiac effects of released
catecholamines. It has also been suggested that the inotropic
actions of protaglandins are secondary to a direct relaxation of
coronary vessels. Nutter and Crumly (1972) observed that PGE^
and PGA^ dilated coronary vessels after B adrenergic blockade.
They also showed, however, that PGA had the largest inotropic
action but had less coronary dilator effect than that of PGE^.
Their results therefore, do not support the hypothesis that the
cardiac affects of prostaglandins are secondary to coronary
dilatation.
The mechanism of the inotropic action of PGE^ has been studied
in the isolated perfused hearts of frog and rat , with similar
results in both preparations. The inotropic action is enhanced
+ 4-h
by a high K /Ca ratio (Vergroessen and de Boer 1968). Hearts
arrested by a high potassium concentration can be restored to
rhythmic contractility by PGE^ but only in the presence of an
adequate calcium concentration (Piceinini et al 1969). It seems
possible, therefore, that the action of PGE^ on the heart may be
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related to an action on calcium influx.
An interesting observation from the uncontrolled tests
in the dog should he noted. Figure 29 shows that divergent
effects on dP^ max and on SW have been produced because of the
dt
combination of the klinotropic and the vasodilator actions of
prostaglandins. Thus although d_P max is still increased,
dt
in the uncontrolled state, there is no change in SW.
GENERA!, DISCUSSION
In recent years much research has been done in an attempt
to quantitate the contractile state of the heart and in particular
to find a single index that will reflect changes in myocardial
contractility. A change in contractility is usually defined as
a change in the performance of the heart that arises from changes
in the relationship during the 'active state' among force, velocity,
fibre length and time after excitation. By definition, therefore}
changes in performance arising simply from changes in physical
conditions outside the contractile system would not constitute
a change in contractility. For this reason, the search for an
index of contractility has been centred around those which may
be independent of preload and afterload. If as defined it is
assumed that changing the afterload does not alter contractility,
events in the isovolumic phase of contraction ought to be unaffected
by changes in afterload. Attention has therefore been focused on
indices derived from this phase of ventricular contraction,
particularly those which reflect the velocity of shortening of the
contractile element, e.g. dP max. We have shown, however, that
dt
dP max is not independent of changes in LVEDP and MAP over the range
dt
which we studied. These results confirm previouswork from which
it has been concluded that d_P max provides a means of detecting
dt
alterations in the contractile properties of the heart, only if
haemodynamic variables, such as 11R, MAP and LVEDP do not change.
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As a result of these findings, most of the recent work has been
done to try and find indices derived from dlj max which correct
dt
for changes in preload and afterload (Davidson et al (974).
We would propose that this line of research lias only a
limited application because the effects of an intervention on the
following three features must be noted before a complete character¬
isation of an inotropic response can be made.
1. rate of rise of active state
2. peak active state.
3. duration of active state.
Obviously any one index will not describe the overall contractility
of an isolated segment of muscle or the whole heart but indices
such as dP max are used to reflect changes in contractility because
dt
the majority of inotropic interventions alter the speed of contract¬
ion and the force of contraction in parallel and also because the
importance of changes in the duration of contraction are often not
realised. We attempted to show that situations do occur in which
the duration of contraction can determine the strength of contract¬
ion or in which force and velocity of contraction are changed in
different directions such that purely a change in (IP max would not
dt
reflect the complete inotropic effect.
Work on isolated muscle has shown that tension development
or muscle shortening may he limited by an abbreviation of the
contraction whereas a prolongation of the contraction increases the
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work done either by increasing the time available Cor tension to
develop or for shortening to occur. (Blinks and Koch-Weser 1963).
The results of isolated muscle studies suggest that drugs such as
sotalol and bretylium produce a positive inotropic effect by
prolongation of the duration of the contraction. (Parmley et al
1972: Markis and Koch-Weser 1971). We, therefore, investigated
the inotropic actions of these drugs to see if the effect occured
in the whole heart and if so, whether such an action would be
reflected by a change in SW but not in d_P max.
dt
Our results showed that only sotalol increased the duration
of the ECG and of the contraction. This effect, however, was
not large enough to be reflected as an increase in SW. The
results obtained in the whole heart are surprising since the
effects on duration in isolated muscle were quite marked. The
discrepancy between our results and those obtained in isolated
muscle preparations could be due to -
1. a difference in the effective concentration of drug used.
The effects of sotalol and bretylium on the relaxation process
-4
were observed with concentrations of 10 M. As we investigated
the actions of cumulative doses up to 32 mg/kg , which is
approximately 10 ^M, it is most unlikely that a difference in
dose of drug can explain the discrepancy.
2. a difference in the rate at which the isolated and whole heart
muscle were paced. Because of the problem of ensuring adequate
oxygenation of the tissue, isolated muscle is usually paced at
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rates below 30/min, whereas our hearts were paced about 140 beats/
min. Blinks et al (1972) have shown that the prolongation o£ the
contraction observed with the methylxanthincs is highly
dependant on the frequency of contraction. The effect of caffeine
on the duration of contraction and the developed tension was
decreased as the interval between contractions was reduced from
300 to 3 seconds. Similar studies have not been done with sotalol
and bretylium, however, it seems likely that their action on the
relaxation process may be reduced in the whole heart as a result
of the higher frequency of stimulation.
Although we have been unable to show the importance of drug
induced increases in the duration of contraction, there is much
evidence in the literature to support our conclusion that changes
in the duration of contraction can produce divergent effects on
parameters which measure velocity of contraction and the amount of
work done in a contraction.
With the induction of acute hypoxia, for example, a decrease
in contractility is observed without a change in the speed of
contraction. Tyberg et al (1970) determined Vmax and Po from the
force-velocity relationship, in isometric contractions of cat
papillary muscle subjected to hypoxia and subsequent reoxygenation.
Initially Po fell to 69% of control values, although Vmax had
decreased only slightly. The fall in Po was accompanied by a
decrease in the duration of contraction. After 60 minutes of
hypoxia, Vmax had also fallen to 46"L of control values. During
early reoxygenation, Vmax increased only slightly from its level
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following hypoxia: whereas the duration of contraction became very
prolonged, resulting in the restoration of force development to
76% of the control value. The authors suggested, therefore, that
the changes in the force of contraction involved the interaction
of two effects, with the onset of hypoxia, the duration of 'active
state' vjas abbreviated whereas the intensity (i.e. the rate of
development) of 'active state' only declined later. With recovery
the duration of 'active state' was immediately prolonged whereas
the intensity returned to normal slowly. Similar results have
been reported in the intact dog ventricle. (Benzing et al 1974).
They found that if myocardial ischaemia was produced by interruption
of coronary flow then mean left ventricular power was significantly
reduced to 50% of the control values whereas Vmax was still 95% of
its control value. This study did not include data of the
corresponding effects on the duration of contraction and so it is
not possible to say whether these changes in the intact heart were
accompanied by similar changes in the duration of contraction
observed in the isolated muscle studies.
Tie se results from isolated muscle and the intact heart do
show, however, that hypoxia effectively reduces the number of
tension generating sites, possibly by reducing the time available
for activation, although the speed with which each individual unit
contracts is unaffected.
The effects of changes in temperature on muscle function
provide another example of a situation in which duration effects
are of great importance.. Kruta ( 1937, 1938) has made a detailed
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study of the inotropic effects of a change in temperature in
isolated guinea pig atria. His results show that a decrease
in temperature, at a constant frequency, decreases the rate
of development of tension in an isometric contraction but
increases the strength and duration of contraction. These
results have been confirmed in cat papillary muscle. Cooling
from 37° to 19.5°C increases the duration of contraction five
fold: this effect beirg associated with a prolongation of the
action potential (Trautwien and Dudel 1954). The positive
inotropic effect of a decrease in temperature has also been
confirmed in the heart in situ (Cotten and Brown 1957). It is
postulated that the change in contractile force of the cooled
myocardium (which is in the opposite direction that one might
expect from the known temperature dependence of the high energy
I |
phosphate metabolism) is mainly due to the increased ca influx
into the myocardium which occurs as a result of the prolongation
of the action potential (Kaufmann and Fleckenstein 1965).
The results of our experiments provide another two examples
of situations in which force and velocity may not be changed in
parallel. Increments in heart rate increased d_P max although peak '
dt
systolic pressure was unchanged. This reflects that the speed of
contraction was altered but the force of contraction was unchanged.
A similar effect was observed if noradrenaline was administered
when the heart was paced at a very fast rate. In this situation,
the heart was probably already working at the upper limit of its
contractile strength and the duration of contraction was so much
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reduced that noradrenaline was only able to increase djP max
dt
and not peak systolic pressure and hence SW.
The examples given above stiow that any one derivation from
the force-velocity-length-time relations will be inadequate
to fit all circumstances. In such situations assumptions are
not warranted despite the fact that simple contractile indices
may be useful in a given limited circumstance. As has been
shown it is not always true to say that an increase in d_P max
dt
represents a positive inotropic effect. The existing terminology
used in studies of cardiac function does not provide for such
situations, because the various facets of myocardial contractility
have been lumped together and designated by this single term.
This way of thinking can lead to confusion and conflicting
reports. This is exemplified by the experiments which have been
done to assess myocardial and circulatory effects of bacterial
endotoxin. Goodyer (1967) who used dP max as an index of
dt
contractility concluded that, in the dog, ventricular contractility
was maintained after endotoxin. In contrast to these findings,
Solis and Downing (1966), in a modified areflexic cat heart-lung
preparation, showed that following endotoxin administration there
was a progressive myocardial deterioration, as indicated by a
decrease in stroke volume at constant LVEDP, IIR and MAP. In
order to explain the discrepancy in the results, Parratt (1973)
repeated these studies in an intact cat preparation, in which
simultaneous measurements of d_P max and cardiac output were made.
dt
He showed that after endotoxin, 11R and d!P max wore increased,
dt
1136
LVEDP was unchanged but MAP and SW were considerably reduced.
The author concluded that because there was a rise in d_P max,
dt
myocardial contractility had been maintained by increased
sympathetic discharge. This conclusion was made in spite of
the fact that cardiac output and SW were reduced as a consequence
of which the animals died in circulatory failure. A similar
effect was seen in our experiments involving the action of
prostagladins in the dog. Under uncontrolled conditions,
prostaglandins increased d_P max although SW was unchanged. In
dt
these cases it is not possible to equate changes in d_P max
dt
with changes in the performance of the heart as a pump and,
therefore,it is misleading to state that contractility is
maint ained.
The first step in an effort to classify the cellular mode of
action of inotropic interventions must be to distinguish between
the various facets of contractility. To do this, one must think
of changes in contractility in terms of the fundamental properties
of muscle rather than in terms of some index which is only
appropriate to the conditions of a particular set of experiments.
Furnivalet al (1970) used a decrease in the duration of systole
as an index of a positive inotropic effect induced by isoprenaline.
This is an example of a situation in which an index has been chosen
purely to suit the conditions of that particular experiment, because
in terms of the mechanical properties of muscle it is wrong to say
that a decrease in the duration of contraction represents a positive
inotropic effect.
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We support Reiter's suggestion (1972) that the term
klinotropic be revived to describe changes in the rate of
development of force and that inotropic interventions should
be classified according to their klinotropic effect and also
their effect on the duration of contraction, because an under¬
standing of inotropic effects in terms of these properties seems
essential for further progress. It follows directly from this
opinion that any single index of contractility will not be
universally applicable and therefore we would question whether
the goal of developing such an index is an attainable one.
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TABLE A .
The effect of changes la HR on dP max, SW and cardiac power.
—
dt
Heart Rate dP max SW MAP LVEDP cardiac power
dt
-1
beats/min mm Ilgs m.T mm Hg mm Hg watts >tC,
113 1595 80.3 70 2.3 9.07 ><j0
121 1658 77.3 67 2.5 9.35
129 1656 64.3 68 2.3 8.29
139 1687 56. 7 71 2.4 7.88
150 1722 45. 8 69 2.2 6.87
170 1220 39.5 80 5.3 6 . 71
188 1390 48.9 78 5.0 9.19
208 1366 36.5 79 4.9 6.86
234 1500 38.2 78 5.2 8.94
150 1310 45.1 81 3.6 6. 77
163 1405 36.6 80 3.5 5.97
179 1488 36.5 78 3.7 6 .53
197 1506 27.4 79 3.5 5.4
208 1937 12.2 80 3.8 2.54
156 1519 78.6 85 1.7 12.26
170 1621 78.3 85 1.4 13.31
188 1637 58.2 83 1.5 10.94
208 1850 58.0 86 1.4 12.06
16 3 1377 59.4 81 1.6 9.68
179 1719 82.6 82 1.9 14. 8
197 1781 62.8 83 1.9 12.4
221 1930 58.3 84 1.8 12.9
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TABLE B .
The effect of MAP on dP max and SW.
dt
MAP dP max SW LVEDP HR
dt
t
mm Hg mm Hgs mJ mm Hg beats/min
58 1217 43.5 4.5 150
81 1429 53.3 4.5 150
111 1562 77. 7 4.9 150
115 1630 70.1 4.9 150
56 16 83 55.1 2.8 139
70 1767 60. 7 2.4 139
87 1909 90.9 2.4 139
96 1972 97.2 3.0 139
90 1632 77.7 4.1
l
156
97 1644 88. 7 4.2 156
100 1668 81.1 4.0 156
105 1725 90. 7 4.1 156
115 1845 110.1 4.1 156
66 1760 66. 7 3.0 163
74 1939 80.2 2. 7 163
89 2122 90. 8 2.8 163
106 2507 139. 8 3.0 163
85 1563 82.4 2.0 156
91 1596 80. 7 1.8 156
100 1718 93.4 1.8 156
113 1749 98.3 1.7 156
125 1943 110. 7 1.9 156
140
TABLE C
The effect of LVEDP on dP max and SW.
' dt-"




mm llgs mj mm Hg beat s/min
0.0 941 14. 8 82 150
0.8 1145 23. 8 81 150
1.5 1301 30.5 83 150
2.6 1364 33.5 89 150
0.9 1422 39.2 75 16 3
1.6 1645 60.5 78 163
1.9 1702 68.3 80 16 3
3.6 1786 72.4 79 163
4.9 1793 90.2 81 163
2.5 1130 8.3 61 150
3.3 1232 22. 9 63 150
4.8 1335 32.8 64 150
5.8 1381 39.8 65 150
7.2 1428 49.3 66 150
0.6 1455 28.8 77 150
1.6 1558 35.6 75 150
2.5 1787 55. 7 78 150
4.2 1698 72. 8 76 150
4.8 1858 85 .2 79 150
1.0 1341 23.3 83 150
2.6 1368 38.0 80 150
3.5 1511 47. 7 80 150
4.2 146 8 50.5 80 150
5.1 1561 68.8 84 150
6.0 15 86 75.5 83 150
1.6 85 8 26.1 76 156
3.1 1004 32.3 76 156
3.9 1036 44.4 74 156
4. 7 1149 48.0 75 156
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TABLE D
The effect: of noradrenaline on dP max, SW and PSP measured at
constant MAP, Hk and LVEDP.
Rate of dP max SW MAP LVEDP HR Conven- Peak
infusion dt t ioiia 1 systolie




ug/kg/min mJ mm Hg mm Hg /min mJ mm Hg.
0 1901 26.0 78 2.2 170 25.4 98
0.21 4007 48.2 81 2.0 170 41.4 117
0 1998 27.5 75 2.1 170 27.3 100
0.41 4785 49.1 77 1.9 170 41.5 124
0 1187 51.5 77 3.1 150 50.4 94
0. 11 2133 66 . 7 83 2.9 150 62.1 102
0 1535 52.9 79 4.4 170 55.6 100
0.05 2251 54. 8 79 3.9 170 58.4 104
0 1724 35 .1 77 1.8 170 26 .6 97
0. 12 1966 40.5 77 2.1 170 30. 7 100
0 1726 31.2 84 1.3 170 i 25 . 7 96
0.25 2799 38.2 85 1.5 170 30.5 104
0 2983 36.2 90 2.0 221 32.3 109
0. 142 4245 51.9 89 1.8 221 43. 8 115
0 2262 31.8 91 0.9 188 20.5 121
0. 1 2445 35.2 92 1.3 188 23.2 121
0 1725 48. 8 88 2.0 188 35 . 1 128
0.14 23 76 71. 8 92 2.0 188 47. 7 150
0 1404 36.9 93 2.5 179 32 .4 117
0. 15 2710 61.8 95 2.0 179 46. 7 133
0 1552 73.5 91 1.8 179 46 . 1 120
0.05 1759 74.1 87 1.4 179 45.1 122
0 1771 69.8 98 1.1 179 46 . 9 124
0.1 2689 102.9 98 1.2 179 57.3 143
0 1917 75.9 88 1.0 179 45 .6 126
0.2 2714 91.4 89 0.9 179 49. 7 143
0 2073 80 86 2.2 208 49.2 109
0.05 2 883 125 86 2.5 208 67.5 139
0 2 004 75 . 9 81 1. 7 208 45 .2 122
0. 1 2597 94.2 81 1.6 208 49.6 130
0 1599 6 3.3 70 2 . 2 208 41.9 109
0.2 2598 101. 7 73 1.9 208 50.5 130
0 1905 92 . 9 73 2.8 208 62.1 117
0.4 2826 12 8.6 76 2.4 208 72. 8 139
0 2413 5 8.3 97 1. 7 208 38. 7 144
0. 16 2 732 55.5 98 1.9 208 37.8 144
0 2 791 76 95 2.5 208 46 . 7 152
0. 32 3 74 7 77 94 2.6 208 45 .0 154
0 2601 78. 3 96 2.4 208 51.1 148
0.08 2915 86.2 98 2. 7 208 52. 7 152
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Table D . Continued:-
Rate of dP max SW MAP LVEDP 11R Conven- Peak
infusion dt tional systolic




ug/kg/min mm Hgs mj mm Hg mm Hg / inin mj mm Hg.
0 1762 47.2 81 2.6 179 28.0 124
0. 16 2937 75 .5 82 2.5 179 39.3 148
0 16 74 39.5 79 2.7 179 25.2 128
0.32 3544 84. 9 84 2.5 179 41.3 16 8
0 2075 52.6 85 3.1 179 33.3 116
0.08 2448 64.4 87 3.1 179 37.6 128
0 1631 54. 7 68 3.2 139 35 .3 112
0. 19 2617 85.6 64 3.7 139 45.9 136
0 1926 68.2 81 3.3 179 43.1 132
0. 15 2286 66.4 85 3.3 179 42.9 136
0 1896 58.9 82 3. 1 179 39.2 128
0.3 2187 52. 9 79 3.1 179 35 . 7 128
0 1929 77.6 118 4.5 150 51.8 141
0.08 2927 90.0 119 4.4 150 58.6 148
0 2188 89 92 2. 7 156 37.5 107
0. 133 2547 92 92 2.3 156 37.5 107
0 2044 42.2 84 5.6 221 31.3 97
0.133 2 800 69.8 88 5.0 221 f 49.2 107
0 1508 75.8 92 4.1 144 75.9 109
0.107 1901 89.1 92 4.0 144 85.6 110
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TABLE E
The effect of Increasing Heart: Rate on Peak svstolfc Pressure
and the duration of contraction and svstole.
Heart Rate duration of duration of Peak systolic
contract ion systole pressure
beats/min ms ms mm Hg
156 260 217 101
170 253 207 98
188 247 207 104
208 233 193 100
234 210 16 7 99
113 330 267 117
121 330 2 73 119
129 323 263 115
139 303 247 112
150 307 248 110
150 2 85 219 103
163 269 210 100
179 247 193 103
197 230 179 95
208 230 173 91
156 243 200 102
170 230 187 101
188 217 175 97
208 201 16 7 98
231 205 163 98
16 3 250 193 106
179 240 187 106
197 230 177 108
221 223 173 106
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TABLE F .
Effect of sotalol on normal dogs.
Experi- Tot a 1 dP max SW MAP LVEDP HR Duration Duration Duration
ment dose of dt 4
mj mm 11g mm Ilg beats/
o f of of
number sotalol mm Hgs ventric- systole ECG
mg/kg
min
u lar ms ms
pres sure
pulse ms
K 38 Control 1256 37.8 74 2.6 150 no recor d on tape
1 1180 37.3 75 2.5 150
2 1231 42.5 74 2.7 150
4 1231 41.9 73 2.7 150
8 13 96 44. 7 75 2.7 150
16 1396 49.3 75 2.6 150
K 46 Control 1982 63.8 81 4.3 179 240 212 197
1 15 84 52.1 80 4.4 179 250 215 210
2 1549 52.3 81 4.7 179 260 225 208
4 1473 45 .3 79 4.1 179 260 220 213
8 1548 48.3 79 4.1 179 257 218 223
16 1528 54. 7 78 4.2 179 2 75 237 220
K 43 Contro1 1606 34.0 73 2.5 134 2 95 237 No ECG
1 1526 32.2 71 2.5 134 2 94 238 on
2 1474 33.2 72 2.9 134 312 239 record
4 1438 27.1 69 2.7 134 312 247
8 1544 34.8 75 2.7 134 313 252
16 1385 31.3 67 2.4 134 313 249
K 51 Control 932 56. 8 72 5.0 110 310 257 7 50
1 909 51.9 70 4.8 110 322 263 2 83
2 904 55 . 9 69 5.0 110 330 258 292
4 9 76 59.1 72 5.3 110 327 255 297
8 918 54. 9 72 5.2 110 330 263 2 94
16 876 46 . 9 72 5.3 110 333 2 70 297
TABLE C .
The effect ofpropranolol on normal dogs, while HR, MAP & LVEDP
are held constant
Ex per L- Dose of dP max SW MAP LVEDP 11R Durat ion Durat ion
ment Propranald dt
-1
mJ mm Hg mm Hg beat s of of




K 41 Control 2591 42.4 83 2.3 188 180 No ECG on
0.1 15 76 23.1 83 2.6 188 207 record
0.2 2013 36.3 77 2.3 188 209
0.4 1851 31.5 73 2.2 188 210
0.8 1038 9.9 74 2.0 188 212
1.6 1464 16.6 80 1.9 188 237
3.2 1475 20. 7 77 1.4 188 212
K 47 Cont ro1 1511 63.6 75 2.2 170 228 216
0.1 1294 44.0 73 2.1 170 232 216
0.2 1202 29. 7 75 2.2 170 224 214
0.4 12 72 30.1 75 2.1 170 232 220
0. 8 1229 27.9 75 2.1 170 230 216
1.6 1026 23.0 72 2.1 170
3.2 929 21.8 72 2.1 170
00 Cont rol 1523 42. 7 72 3.2 179 232 208
0.05 1318 33.4 70 3.2 179 238 208
0.1 1442 37.6 73 3.1 179 232 208
0.2 1241 30.5 69 3.2 179 232 208
0.4 1259 33. 1 73 3.3 179 232 209
0.8 1230 33.5 76 3.3 179 238 200
1.6 1120 30.4 74 3.2 179 240 200
3.2 1031 27.8 77 3.5 179 248 208
TABLE H
The effect of sotalol on reserpinized dogs while HR, MAP & LVEDP
are held constant.
Experi- Dose of dP max SW MAP LVEDP HR Duration Duration Duration
ment sotalol dt
-1
mJ mm Ilg mm Hg beat s of ventri of of ECG
number mg/kg mm Hgs /min cu lar systole ms
pressure ms
pulse ms
K 77 Control 1271 56.2 82 2.2 129 267 232 210
1 1241 55.7 74 2.0 129 267 229 210
2 1193 52.7 79 2.3 129 2 73 234 227
4 1137 45 .3 81 2.6 129 2 73 232 227
8 1090 40.4 79 2.3 129 2 80 235 232
16 1207 52.5 76 2.2 129 2 84 240 237
32 1098 42.3 80 2.1 129 2 82 233 233
K 80 Control 2358 97.6 92 1.8 13 9 237 212 217
1 142 7 65 .6 88 2.1 139 247 217 220
2 1472 73.0 94 1.8 139 250 213 217
4 1357 65. 7 94 2.0 139 253 215 222
8 1197 57.8 93 2.0 139 253 218 215
16 1145 64.2 91 1.9 139 253 217 217
K 86 Control 1290 114.4 65 3.2 121 290 252 2 85
0.25 1312 123.6 63 3.0 121 287 252 2 82
0.5 1384 128.2 62 2.8 121 287 252 2 88
1.0 1366 126 . 7 61 3.2 121 290 256 287
2.0 1494 106.6 67 2.6 121 300 252 291
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TABLE I
'['lie effect of nronrann lo 1 on reserpinized dogs.
Experi¬ Dose of d P max SW MAP LVEDP HR Du rat ion Duration Duration
ment propranalo] dC
-1
mj mm Hg mm Hg beat s of o f of ECG




K 81 Control 1409 54.8 78 3.5 179 255 215 220
0.1 1733 60.2 80 3.7 197 233 202 208
0.2 1659 55 .4 80 3.3 197 238 207 213
0.4 1518 69.1 78 3.8 179 253 222 225
0.8 1635 76.9 82 3.2 179 255 223 227
1.6 1451 55.5 80 3.7 179 255 217 227
K 82 Contro1 1385 59.2 84 3.3 144 2 92 227 257
0.1 1417 55.7 85 3.2 144 287 225 263
0.2 1388 50. 9 84 3.1 144 288 228 260
0.4 1402 48. 7 84 3.5 144 287 220 257
0.8 1428 46 .5 81 3.4 144 287 218 265
1.6 1306 42.5 81 3.4 144 293 228 262
3.2 1110 39.1 78 4.3 144 2 93 232 257
K 83 Control 1454 64.9 84 5.3 170 250 197 192
0. 1 1528 57.0 82 5.4 170 245 193 192
0.2 1524 61.4 85 6.0 170 250 200 193
0.4 15 93 67.2 79 5.3 170 250 208 193
0.8 1729 79.6 80 5.2 170 240 200 193
1.6 1644 70. 7 77 5.3 170 247 200 190
3.2 1709 78.5 86 5.6 170 260 200 233
71 CO CO Control 1711 43.9 71 2. 7 144 258 203 217
0.1 1393 25. 9 73 2.9 144 26 7 205 218
0.2 1319 27.1 65 2.8 144 257 202 215
0.4 1436 33.4 69 2.8 150 258 207 213
0.8 1529 37.3 74 2.9 150 253 207 203
1.6 1402 29. 9 68 2.8 150 255 2 05 203
3.2 1303 2 9.2 68 2.8 144 26 3 207 207
148
TABLE J
The effect of sotalol on dors, pretrented with practalol.
Exper i- Dose o£ d[' max SW MAP LVEDP HR Duration Duration Duration
raent sotalol dC
-1
mj mm Hg mm Hg beats of of of ECG




K 95 Cont ro1 2207 68.3 85 1.2 139 2 74 221 233
1 2150 64.3 83 1.4 139 277 227 243
2 2394 80.0 88 1.7 139 289 232 252
4 2206 65.2 88 1.5 139 293 230 248
8 2078 59.3 82 1.6 139 298 230 262
16 1839 50. 7 89 1.5 139 313 247 263
K 96 Cont ro1 1998 77.8 101 0.5 150 26 7 203 210
1 1972 74.9 101 0.6 150 270 203 210
2 2061 84.3 95 0.7 150 270 207 214
4 2008 76 . 7 97 0.6 150 277 207 214
8 1915 76.4 97 0.6 150 2 82 212 222
16 1881 75.0 99 0.6 150 287 221 230
32 1915 78. 1 102 0.6 150 292 225 233
K 98 Control 2453 39. 1 94 1.1 150 278 215 249
1 2336 34.6 93 1.1 150 278 215 256
3 2289 34. 9 93 1.2 150 287 213 266
8 2462 2 7.2 92 1.1 150 287 215 263
16 1970 16 .4 81 2.3 150 298 215 263
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TABLEK .
The effects of hretvlium, measured as constant MAP, hVEDl' and HR
















mg/kg mm Hgs mj mm llg mm Hg beat £
/ m i n .
ms ms ms
0 1196 69.8 67 2.7 139 248 no no ECG
0.1 1256 83.1 67 2.6 139 242 pulsatile on tape
0.2 1309 92.6 67 3.0 139 235 aortic
0.4 1469 85.0 69 3.0 139 235 pressure
0.8 1444 83.3 64 2.9 139 234
1.6 1471 86. 7 68 3.0 139 235
3.2 1449 84.2 66 3.0 139 235
6 .4 1412 76 .1 68 3.0 139 238
12. 8 1404 73.5 64 2.9 139 248
25 .6 1432 82.5 67 2.9 139 245
0 1600 69.5 80 1.5 150 234 , 202 no ECG
0.1 1810 73.5 80 1.4 150 236 195
0.2 1807 72.5 80 1.6 150 233 193
0.4 1891 72.0 82 1.5 150 230 193
0.8 215 8 104.1 84 1.3 150 220 188
1.6 2264 117.0 88 1.4 150 218 187
3.2 2219 103.4 77 1.8 150 223 189
6.4 2185 90. 1 76 1.6 150 219 185
12. 8 2248 103.2 79 1.5 150 216 180
25.6 2263 105 . 9 80 1. 7 150 220 190
0 1226 52.5 61 1.3 125 2 76 228 223
2 1147 51.9 56 1.2 125 271 232 223
4 1365 57.3 58 1.2 125 260 220 221
8 1365 57.9 60 1.2 125 247 217 2 26
16 1466 60. 8 60 1.1 125 2 70 220 230
32 1417 57.2 64 1.5 125 260 2 14 222
64 1525 61.4 60 1. 1 125 263 217 2 2 2
0 1743 52.8 77 1.2 156 271 220 250
1 1642 48.5 74 1.2 156 2 70 218 250
2 1714 55.0 76 1.5 156 273 218 250
4 1506 39.9 72 0.9 156 2 73 220 253
8 1629 41.0 76 1. 1 156 2 73 217 253
16 1578 38.4 72 0.9 15b 270 2 15 25 1
32 1759 48. 7 76 1.1 156 260 211 246
64 1945 5 2.1 76 1.2 156 2 56 2 10 243
0 936 6 7.3 93 2 . 2 110 293 246 24 8
1 10 74 99. 9 88 1.8 110 293 249 243
2 1099 107.8 92 2 . 1 1 10 285 246 249
4 1120 116.4 93 2. 1 110 2 83 240 25 3
8 1083 108. 9 91 1 . 9 110 2 86 246 25 3
16 1048 102 . 8 91 2 .0 1 10 2 86 2 40 248
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TABLE L .




B rety 1 iura
dP max
dt














































































































































































The effect of PGC In the cat, on dP max and SW when MAP and
dt















Contro1 1859 21.3 91 0.9 208
PCC2 0.17 1278 13.4 51 0.5 208
Control 1742 15.3 88 2.8 208
PGC2 3.3 1270 11.1 52 2.0 208
Control 1544 17.3 68 5.4 208
PGC? 0.06 1091 11.7 43 4.7 208
Control 1379 14.1 73 3.7 208
PCC2 0.16 1013 8. 8 49 3.0 208
Control 2070 19.2 91 3.3 197
PGC2 0.14 1420 13.0 63 3.1 197
Control 2076 00r—1 88 2.4 208
PGC2 0.28 1564 11.6 68 2.4 208
Control 1525 14.4 67 1.4 188
PGC2 0.44 1236 9.8 57 1.5 188
Control 3043 48.0 128 2.6 221
PCC2 0.33 1221 13.8 52 1.9 221
Contro1 3617 54.9 140 2.1 234
PGC2 0.06 3319 29.2 127 1.6 234
Control 45 7 7 33.6 135 4.1 16 3
PCC. 5.6 2875 20. 7 76 3.0 163
Contro1 3306 28.4 123 4.4 163
PCCL 5.6 1425 9.4 49 3.5 16 3
Control 2 800 25.2 94 4.6 150
PGC, 1.7 658 12.2 37 4.3 150
Control 13 86 18.5 76 4.2 150



























The effect: of PGC and FOB on dP max and SW in the cat, while HR,
dt
MAP and LVEDP were held constant
Dose of PG d P max SW MAP LVEDP 11R
dt
-1
mm Hgsug/kg/min mj mm llg mm Hg beat s/min
Control 3043 18.6 121 1.9 234
PGE9 1.65 3338 19.6 120 2.0 234
Control 2770 28.2 133 1.8 221
PGE2 0.33 3237 18.0 133 1.7 221
Control 25 86 22. 7 95 4.2 150
PGE9 0.83 2654 24.6 95 4.5 150
Control 1644 17.1 82 4.1 150
PGE2 0.83 1710 18.6 83 4.2 150
Control 3 765 33.4 139 4.8 163
PGEl 2.8 3455 28.4 140 4.7 163
Control 3608 32.5 140 4.9 163
PGEl 2.8 3601 30.5 141 4.9 163
Mean baseline 2903 25.4 118 3.6 180









Control 2 985 38.7 128 2.1 221
PG^ 5.6 2 985 39.9 132 2.3 221
Control 3300 28.4 123 4.4 163
PGC1 5.6 3408 23.9 129 4.5 163
Control 2 800 25 .2 94 4.6 150
PGC2 1.7 2850 26 .5 95 4. 7 150
Control 1380 18.5 76 4.2 150
PCC9 1.7 1374 18.0 76 4.2 150
Cont ro1 3043 32 .4 12 8 2.6 221
PGC2 0.33 3072 26 .0 125 2.6 221
Control 3617 36 .6 140 2 . 1 2 34
PCC9 0.06 3 726 35 .6 141 2 .2 234
Mean baseline 2854 2 9.9 115 3.3 190













The effect of PCC and PCE on dP wax and SW, in Che dog, while
dL
11R, MAP and LVKDP are held constant:.
Dose of pg dP max SW map lvedp HR
dt
.. -1
mm Hgsug/kg/min mj mm llg mm Hg beat s/min
Control 1292 38.0 74 3.4 156
pge2 1 2117 47.8 71 3.7 156
Control 1080 38.6 68 4.0 156
pge2 1 16 77 58.3 67 3.7 156
Control 1357 58.1 81 1.6 179
pge2 0.28 2133 76.4 79 1.7 179
Control 1628 76.6 85 1.3 179
pge 0.07 2085 82.0 84 1.3 179
Contro1 1125 31.3 75 2.6 179
pge2 0.07 1534 55.7 77 2.6 179
Control 1055 36.2 62 3.3 179
PCE2 0.28 16 36 54.1 65 3.4 179
Mean baseline 1256 46.5 74 2.7 171






- 2.6 : - -
Contro1 1431 52.1 75 3 . 7 156
PCC? 1 2148 58.1 73 3.7 156
Contro1 1708 73.4 83 1.4 179
PCC2 0.07 2126 81. 7 81 1.4 179
Control 9 77 35. 1 61 2.6 179
PCC2 0.07 1135 41.9 60 2.4 179
Contro1 1041 32.8 6 7 1.6 179
PCC2 0.28 13 95 50.4 6 9 1.9 179
Mean baseline 12 89 48.4 72 2.3 173













The effect of PCC and PGE on dP max and SW, in the dog,
.
dt
when MAP and LVEDP were allowed to change.
Dose of PG dP max
dC
-1
SW MAP LVEDP HR
ug/kg/min imn Hgs mj mm Hg mm Hg beat s/min
Contro1 1638 45.2 73 3.4 156
PGE2 1 2241 44.5 53 3.7 156
Control 2069 27.7 95 1.6 179
PGE2 0.28 32 76 29.8 80 1.7 179
Control 2414 35 .5 100 1.3 179
PGE2 0.07 3103 33.4 90 1.3 179
Control 1417 64.8 80 1.8 179
PGE2 0.07 1903 67.4 69 2.3 179
Control 1305 58.3 83 2.5 179
PGE2 0.28 1602 56.4 65 2.2 179
Mean baseline 1769 46 .3 86 2.1 174






40.9 "*2.0 +0. 1to. 1 -
Control 1412 64.1 81 1.3 179
PCC9 0.07 1712 62.1 70 1.7 179
Control 1262 52.0 81 2.7 179
PCC2 0.28 1710 52.0 67 1.4 179
Mean baseline 1337 58.0 81 2.0 179
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